PSYCHCE

Opioid Use and Its Impact on Clinical Practice



Section 1: Introduction to Opioids and the Scope of the Epidemic

Overview of the Opioid Crisis

The opioid crisis represents one of the most far-reaching public health emergencies of the 21st century. Originally stemming from well-intentioned efforts to alleviate pain, the widespread availability and prescription of opioids have led to staggering rates of misuse, dependence, and mortality. In the United States alone, opioid overdoses claimed over 80,000 lives in 2022, with synthetic opioids like fentanyl driving this surge (Centers for Disease Control and Prevention [CDC], 2023). Globally, opioid-related morbidity and mortality continue to rise, despite growing awareness and policy interventions. The complex interplay between chronic pain management, pharmaceutical practices, and sociocultural dynamics has transformed opioid use disorder (OUD) from a localized issue into a broad societal concern. For psychologists and mental health professionals, understanding the evolving landscape of opioid use is essential to providing competent, ethical, and evidence-informed care.

Classification and Pharmacological Mechanisms of Opioids

Opioids are a class of drugs that exert their effects by binding to specific opioid receptors in the central and peripheral nervous systems. These receptors, mu (μ), kappa (κ), and delta (δ), modulate the transmission of pain signals, emotional regulation, reward, and respiratory function. Opioids can be categorized into natural opiates (such as morphine and codeine), semi-synthetic opioids (such as oxycodone and hydromorphone), and fully synthetic opioids (such as fentanyl and methadone). Endogenous opioids, including endorphins and enkephalins, play a role in the body's natural pain regulation and reward system. Exogenous opioids

activate the same receptor systems with a greater potency and longer duration, which can dysregulate normal signaling.

The mu-opioid receptor, in particular, is responsible for the primary analgesic and euphoric effects associated with opioid use. When opioids bind to this receptor, they inhibit the release of neurotransmitters like substance P and glutamate, which are involved in pain perception. At the same time, opioid activation stimulates dopamine release in the mesolimbic system, especially the nucleus accumbens, leading to reinforcement and increased likelihood of repeated use (Sulman et al., 2025). This neurochemical pathway underlies both the therapeutic effects and the addictive potential of opioids.

Repeated exposure to opioids leads to neuroadaptive changes. Tolerance develops when the body becomes less responsive to the drug, requiring higher doses to achieve the same effect. Physical dependence emerges as the brain adapts to the presence of the drug, resulting in withdrawal symptoms upon cessation. These symptoms, such as nausea, muscle pain, anxiety, and dysphoria, can become powerful motivators for continued use, further reinforcing the cycle of addiction.

Historical Evolution of the Crisis

The modern opioid crisis has evolved through distinct phases, each shaped by specific medical, cultural, and political forces. In the 1990s, pharmaceutical companies aggressively promoted opioid analgesics for chronic pain, reassuring clinicians that the risk of addiction was minimal. The release and marketing of OxyContin by Purdue Pharma in 1996 marked a turning point, leading to a dramatic increase in opioid prescriptions. By the early 2000s, opioid prescribing rates had quadrupled, accompanied by a surge in opioid-related deaths and hospitalizations.

As the addictive nature of prescription opioids became apparent, public health policies began to restrict their availability. This, however, inadvertently contributed to a shift toward illicit opioids, including heroin and, more recently, fentanyl. Fentanyl and its analogs, often clandestinely manufactured and distributed, are 50 to 100 times more potent than morphine and frequently mixed with other substances, resulting in a heightened risk of overdose (CDC, 2023).

Recent years have witnessed an alarming increase in fentanyl-involved deaths, especially among adolescents and young adults. The Drug Enforcement Administration (DEA, 2023) estimates that over 60% of illicit pills sold online and, on the street, now contain potentially lethal amounts of fentanyl. These developments highlight the dynamic and adaptive nature of the opioid crisis, necessitating continuous monitoring and intervention.

Epidemiology and Public Health Impact

The scope of opioid misuse is broad, affecting individuals across all demographic, geographic, and socioeconomic boundaries. According to the National Institute on Drug Abuse (NIDA, 2024), approximately 2.7 million Americans aged 12 and older had OUD in the past year. Overdose deaths have risen steadily, now constituting the leading cause of accidental death for adults under the age of 50.

Disparities in opioid-related outcomes have become more pronounced in recent years. While early waves of the crisis disproportionately affected White, rural populations, more recent data show steep increases in overdose rates among Black and Native American communities (Friedman et al., 2022). These disparities are rooted in historical trauma, systemic racism, and unequal access to treatment. Urban settings have also seen increased fentanyl-related morbidity due to the proliferation of synthetic opioids in the drug supply.

In addition to mortality, opioid use carries significant psychological, relational, and economic burdens. Families are often fractured by addiction, children may be displaced into foster care, and communities may suffer from increased crime and unemployment. The financial cost of the opioid epidemic is estimated to exceed $1 trillion annually in the United States, encompassing healthcare expenditures, criminal justice involvement, and lost productivity (Council of Economic Advisers, 2019).

The Neurobiology of Opioid Use Disorder

From a neurobiological perspective, opioid addiction is not merely a failure of willpower, but a chronic brain disease characterized by cycles of intoxication, withdrawal, and craving. Functional MRI studies have demonstrated that individuals with OUD exhibit structural and functional changes in brain regions responsible for impulse control, emotional regulation, and decision-making, including the prefrontal cortex, amygdala, and striatum (Volkow et al., 2022). These changes compromise an individual's ability to regulate behavior, increasing the risk of compulsive drug-seeking despite negative consequences.

Opioid withdrawal, while not typically life-threatening, can be extremely uncomfortable and psychologically distressing. The anticipation or experience of withdrawal often drives continued use, reinforcing dependency. Moreover, environmental cues, such as places, people, or emotions associated with drug use, can trigger intense cravings through conditioned learning. This neurobiological framework reinforces the need for long-term, integrated treatment approaches that combine medication with psychosocial support.

Co-Occurring Mental Health Disorders

Opioid use disorder rarely occurs in isolation. High rates of co-occurring mental health conditions, including depression, anxiety, posttraumatic stress disorder (PTSD), and personality disorders, complicate diagnosis and treatment. In some cases, individuals initiate opioid use to self-medicate emotional pain, only to find themselves caught in a worsening cycle of dependence and psychiatric instability. Conversely, prolonged opioid use can exacerbate mental health symptoms through neurochemical depletion and social disruption.

The bidirectional relationship between trauma and opioid misuse is particularly significant. Numerous studies have identified childhood trauma, adverse childhood experiences (ACEs), and interpersonal violence as strong predictors of substance use disorders, including OUD (LeTendre & Reed, 2017). Trauma-informed care models are essential for psychologists working with this population, as they emphasize safety, empowerment, and collaborative decision-making.

Gaynes et al. (2025) highlight the effectiveness of culturally adapted interventions, such as the Friendship Bench model, for addressing co-morbid mental health symptoms in individuals with OUD. Integrated behavioral health approaches that combine mental health treatment with addiction care are associated with better outcomes and higher retention rates.

Global and Societal Perspectives

While the opioid crisis is often framed as a uniquely American issue, opioid misuse is rising globally. Countries such as Canada, Australia, and parts of Western Europe have reported increasing rates of opioid dependence, largely driven by overprescription and lack of integrated care models. However, global responses vary significantly, with some nations prioritizing harm reduction and public health approaches over criminalization. Portugal’s decriminalization model, for example,

has led to significant reductions in overdose deaths and incarceration rates using treatment-focused policies.

In the United States, federal responses have included the SUPPORT Act (2018), expansion of medication-assisted treatment (MAT), and increased funding for prevention programs. Nevertheless, inconsistencies in implementation, stigma, and workforce shortages continue to limit progress. For psychologists, understanding both national policy and global trends is critical for informed advocacy and clinical practice.

Role of Psychologists in Addressing the Crisis

Psychologists have a crucial role to play in all stages of opioid prevention, intervention, and recovery. Their expertise in behavior change, motivational interviewing, trauma-informed care, and co-occurring disorders makes them essential members of interdisciplinary teams. Psychologists are well-positioned to conduct comprehensive biopsychosocial assessments, identify risk factors, and offer evidence-based treatments such as cognitive-behavioral therapy (CBT), acceptance and commitment therapy (ACT), and contingency management.

Beyond direct clinical care, psychologists contribute to system-level change by conducting research, shaping public health interventions, and training other providers. They also have ethical obligations under the APA Code of Ethics to engage in continuing education, reduce harm, and advocate for health equity. The integration of psychologists into primary care and addiction treatment settings is supported by a growing body of research emphasizing collaborative care as a best practice model for OUD (SAMHSA, 2022).

Psychologists must also navigate complex ethical landscapes involving informed consent, confidentiality, dual relationships, and mandated reporting. The stigma surrounding substance use can influence client engagement and provider

attitudes, making it essential for psychologists to use person-centered, non-judgmental language and cultural humility in all interactions.

Conclusion

This section has provided an in-depth exploration of the opioid crisis, from its pharmacological roots to its social consequences. Understanding the neurobiology, epidemiology, and historical trajectory of opioid misuse is foundational for effective psychological care. As the crisis continues to evolve, marked by shifting drug markets, policy reforms, and emerging treatment modalities, psychologists must remain informed, flexible, and committed to ethical, evidence-based practice. In the following sections, we will build upon this foundation by exploring diagnostic criteria, assessment strategies, culturally competent interventions, and real-world case applications.

Section 2: Clinical Presentation and Assessment of Opioid Use Disorder in Diverse Populations

Cultural and Clinical Complexity in Opioid Use Disorder

Opioid use disorder (OUD) manifests across every demographic group but does not do so uniformly. Understanding how the disorder presents in diverse populations is essential for clinicians, especially psychologists, who are often involved in early detection, assessment, and ongoing treatment. Assessing OUD requires more than applying diagnostic criteria; it demands cultural humility, developmental awareness, trauma sensitivity, and awareness of how structural inequities impact both substance use and access to care. Clinicians must consider how race, ethnicity, gender identity, sexual orientation, age, language,

immigration status, and socioeconomic factors shape the presentation of OUD and influence client willingness to disclose opioid use or engage in treatment.

The diagnostic criteria for OUD, as outlined in the DSM-5-TR, include a range of behavioral, cognitive, and physiological symptoms such as tolerance, withdrawal, unsuccessful efforts to reduce use, and continued use despite harm. While these criteria provide a framework for diagnosis, they are insufficient in capturing the lived experiences of individuals from diverse communities. Cultural expressions of distress vary, as do coping strategies and meanings attached to substance use. Standardized assessment tools risk overpathologizing certain groups or missing problematic opioid use altogether when cultural context is ignored.

Diagnostic Tools and Cross-Cultural Validity

Psychologists frequently use validated screening tools to assess for substance use, including the Drug Abuse Screening Test (DAST), the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST), the NIDA Quick Screen, and the Structured Clinical Interview for DSM-5 (SCID). These tools provide essential structure but are often normed on primarily White, middle-class populations. As a result, their sensitivity and specificity may decline when used with individuals whose cultural or linguistic backgrounds differ significantly from the populations on which the tools were validated.

For example, certain items may be interpreted differently or carry different social consequences in communities with heightened surveillance or criminalization of drug use. Black and Latinx communities, for instance, are often disproportionately exposed to punitive responses to substance use, leading to underreporting of symptoms during clinical interviews. Research by Redmond et al. (2024) has shown that mistrust of medical institutions and fear of systemic repercussions lead many Black clients to minimize or deny substance use, especially in mandated

settings. As a result, clinicians must adjust their approach, building rapport over time and emphasizing confidentiality, collaboration, and nonjudgmental inquiry.

To improve cross-cultural assessment, the Cultural Formulation Interview (CFI), included in the DSM-5, offers a structured method for exploring how clients understand their problems within cultural frameworks. The CFI includes questions about identity, cultural explanations of illness, support systems, and clinician-client relationship dynamics. It is particularly useful in cases where opioid use may not be the client's presenting concern but is embedded within other psychosocial challenges such as housing instability, chronic pain, or trauma.

Variability in Presentation Across Racial and Ethnic Groups

Opioid use is perceived and responded to differently across cultural groups. Among Latinx populations, cultural concepts like familismo (emphasis on family), personalismo (value of personal relationships), and fatalismo (belief that outcomes are fated) can shape attitudes toward substance use and treatment. López and Melian (2024) found that Latinx clients were more likely to attribute substance-related problems to external factors and may avoid formal treatment due to stigma or language barriers. Moreover, Latinx clients may express psychological distress somatically, making opioid misuse harder to detect if clinicians rely solely on verbal self-report.

In Asian American communities, substance use is often highly stigmatized, and mental health problems may be minimized due to cultural norms of saving face. Wong-Padoongpatt et al. (2024) note that clinicians working with Asian American clients should consider indirect methods of inquiry and emphasize client privacy and confidentiality. Families may play a central role in care decisions, and involving them (with client consent) can improve engagement and trust.

American Indian and Alaska Native (AI/AN) populations face disproportionate rates of opioid-related harms. The legacy of colonization, historical trauma, and forced relocation has created intergenerational cycles of substance misuse in many Indigenous communities. West et al. (2022) emphasize the need for culturally grounded assessments that reflect tribal values, traditions, and healing practices. Standard tools often fail to capture culturally relevant protective factors such as community cohesion, spiritual practices, or traditional ceremonies. Collaborating with tribal leaders and community-based health workers can significantly improve the validity and effectiveness of assessment and care.

Gender Identity, Sexual Orientation, and Minority Stress

Transgender and gender-diverse individuals experience higher rates of opioid misuse compared to their cisgender counterparts. Minority stress theory explains that chronic exposure to stigma, discrimination, and violence leads to elevated risk of psychological distress and substance use as a coping strategy. Ezell et al. (2024) found that transgender clients often use opioids to cope with trauma, social exclusion, or pain associated with gender dysphoria. These clients may avoid seeking help due to fears of misgendering, pathologization, or provider insensitivity.

Assessments must be gender-affirming and trauma-informed, using correct names and pronouns, avoiding assumptions about anatomy or sexual behavior, and incorporating explicit questions about experiences of stigma and discrimination. Inclusive intake forms, visible signs of LGBTQ+ affirmation, and trained staff can reduce barriers and foster trust. In addition to substance use assessments, clinicians should screen for co-occurring conditions such as depression, anxiety, and suicidality, which frequently accompany substance misuse in this population.

LGBTQ+ youth, particularly those who have experienced family rejection, are at increased risk of homelessness and survival-based substance use. Clinicians working with this population should be attuned to the role of unsafe environments, sexual exploitation, and school bullying in shaping OUD risk. Culturally responsive tools that explore identity-related stress and resilience, such as the Gender Minority Stress and Resilience Measure, can enhance assessment accuracy.

Resilience, Structural Barriers, and Integrated Treatment Implications

While minority stress theory provides an essential framework for understanding elevated opioid misuse risk among transgender and gender-diverse individuals, a comprehensive clinical approach must balance attention to vulnerability with recognition of resilience. Research increasingly demonstrates that protective factors such as community connectedness, access to gender-affirming care, supportive family relationships, and positive identity integration serve as significant buffers against substance use and psychological distress (Fish et al., 2020). Gender affirmation in medical, social, and relational contexts has been associated with reductions in depression, anxiety, and suicidality, all of which are known correlates of opioid misuse risk (Green et al., 2022). For psychologists providing comprehensive care, it is essential not only to assess exposure to stigma and trauma, but also to actively explore sources of strength, adaptive coping, and community belonging that may mitigate substance-related risk.

In addition to interpersonal discrimination, structural determinants significantly shape opioid risk among transgender and gender-diverse populations. Limited access to affirming healthcare providers, insurance exclusions for gender-affirming treatments, restrictive state policies, and geographic disparities in specialty

services create systemic barriers that compound stress and restrict preventive care. When individuals experience repeated healthcare discrimination or denial of medically necessary gender-affirming interventions, mistrust of medical systems may increase, delaying treatment for both substance use disorders and co-occurring conditions. Clinicians must therefore conceptualize opioid misuse not solely as an individual coping response, but as a behavior embedded within broader policy and healthcare environments.

Opioids may serve a particularly salient function within this population due to intersecting experiences of physical and psychological pain. Transgender individuals report higher rates of chronic pain, potentially related to minority stress, trauma exposure, and barriers to consistent medical care (Alpert et al., 2017). Additionally, some individuals experience medical trauma associated with stigmatizing or invasive healthcare encounters, which may heighten somatic distress and contribute to self-medication patterns. In such contexts, opioids may function not only as emotional numbing agents, but also as perceived relief for chronic physical discomfort. Understanding these pathways enhances clinical assessment and prevents oversimplified interpretations of misuse as purely recreational or impulsive behavior.

Treatment implications must emphasize integration of gender-affirming care with evidence-based opioid use disorder interventions. Research supports the effectiveness of medications for opioid use disorder such as buprenorphine and methadone across diverse populations; however, engagement and retention improve when services are culturally responsive and affirming (Krawczyk et al., 2022). Integrated care models that combine addiction treatment with mental health services and gender-affirming medical care reduce fragmentation and enhance continuity. Clinicians should ensure that treatment settings consistently use correct names and pronouns, avoid pathologizing identity, and provide staff training in LGBTQ+ competency. Trauma-informed approaches remain essential

and should be paired with empowerment-based frameworks that validate identity and foster agency.

Family acceptance and social support are particularly potent protective factors among LGBTQ+ youth and young adults. Research indicates that parental support and affirming school environments are associated with lower rates of substance use and suicidality (Fish et al., 2020). Interventions that engage families in affirming education, when appropriate and safe, can reduce risk trajectories. At the same time, clinicians must assess for safety in cases of rejection or abuse. Psychologists must work to connect youth to community-based affirming resources. Strengths-based treatment planning that incorporates peer support networks, LGBTQ+ community organizations, and culturally grounded resilience strategies shifts the clinical focus from pathology to empowerment.

Ethical practice requires awareness of how systemic inequities shape access to care and influence treatment outcomes. By addressing both risk and resilience, incorporating structural context, and providing integrated gender-affirming addiction care, psychologists can deliver more equitable and clinically effective services for transgender and gender-diverse individuals experiencing opioid misuse.

Age, Developmental Stage, and OUD Presentation

Opioid use disorder also varies significantly by age. Adolescents and young adults are particularly vulnerable to substance experimentation, peer influence, and risk-taking behaviors. They may engage in episodic, high-dose opioid use without recognizing the dangers of synthetic opioids like fentanyl. Boness et al. (2024) recommend using tools such as the CRAFFT (Car, Relax, Alone, Forget, Friends, Trouble) and BSTAD (Brief Screener for Tobacco, Alcohol, and Drugs), which are

validated for youth and account for developmental stages and school-related functioning.

Older adults present unique assessment challenges. Many are prescribed opioids for chronic pain, arthritis, or post-surgical recovery, and may not identify their use as problematic. Cognitive decline, social isolation, and polypharmacy increase the risk of misuse, yet symptoms may be misattributed to aging or dementia. Providers should use age-appropriate screening tools and maintain a high index of suspicion when evaluating functional changes, falls, or altered mental status in older clients. Psychoeducation, motivational enhancement, and family involvement are critical components of assessment and intervention in this population.

Trauma-Informed and Biopsychosocial Assessment

Trauma exposure is a key driver of opioid misuse. Adverse childhood experiences (ACEs), such as abuse, neglect, and household dysfunction, increase the risk of substance use across the lifespan. Many individuals with OUD have complex trauma histories that shape both their opioid use and their help-seeking behaviors. Trauma-informed assessment emphasizes safety, choice, and empowerment. It avoids re-traumatization by giving clients control over how information is shared and by framing questions in a non-intrusive manner.

A biopsychosocial assessment model allows clinicians to examine the full spectrum of biological, psychological, and social factors influencing opioid use. It includes substance use history, psychiatric symptoms, medical conditions, family dynamics, housing, employment, and legal issues. It also includes strengths and supports, such as spiritual beliefs, community connections, and cultural identity. Integrating trauma screening tools such as the Life Events Checklist (LEC-5) or the

Primary Care PTSD Screen (PC-PTSD-5) can help clinicians identify trauma exposure and inform treatment planning.

Collateral information from family members, community leaders, or medical records can also enhance assessment accuracy, particularly in collectivist cultures where individuals may defer to others in decision-making. Clinicians must obtain informed consent and ensure that information-sharing respects client privacy and autonomy.

Ethical and Structural Considerations

Ethical practice in assessment requires psychologists to remain aware of power dynamics, personal biases, and the limitations of diagnostic frameworks. The APA Ethical Principles of Psychologists and Code of Conduct (2017) emphasize the importance of cultural competence, informed consent, and avoiding harm. In the context of substance use assessment, this means avoiding language that stigmatizes, blaming clients for their substance use, or assuming uniformity in how OUD presents.

Structural inequities such as poverty, criminalization, housing insecurity, and healthcare discrimination shape how individuals experience and respond to opioid use. Sayegh et al. (2023) warn that standardized assessments can become tools of social control when used without context or sensitivity. For example, in child welfare or criminal justice settings, substance use disclosures can lead to punitive outcomes, even when clients are actively seeking help. Clinicians have a responsibility to explain the limits of confidentiality, advocate for therapeutic rather than punitive responses, and work within systems to reduce harm.

Organizational culture also matters. Guerrero et al. (2019) identify key drivers of culturally competent assessment, including leadership commitment, diverse staff, ongoing training, and community partnerships. Providers embedded in

organizations that prioritize equity are more likely to use inclusive assessment tools and to retain clients from marginalized backgrounds.

Moving Toward Inclusive and Effective Assessment

Effective assessment of opioid use disorder is not a one-size-fits-all process. It requires psychologists to integrate clinical expertise with cultural humility, evidence-based tools with client-centered listening, and awareness of systemic barriers with advocacy for justice. By approaching assessment as a relational, ethical, and culturally embedded practice, clinicians can more accurately identify OUD, build client trust, and foster engagement in recovery-oriented care.

Assessments should evolve over time, as client needs and circumstances change. Regular reassessment, shared decision-making, and interdisciplinary collaboration help ensure that treatment remains aligned with client goals and capacities. Whether working in private practice, primary care, schools, community agencies, or integrated care systems, psychologists must be equipped to assess OUD in ways that respect the complexity, dignity, and diversity of those they serve.

Section 3: Intersection of Opioid Use and Mental Health Conditions

Understanding the Intersection of Mental Health and Opioid Use

The clinical relationship between opioid use disorder (OUD) and mental health conditions is complex, multidirectional, and central to effective treatment planning. Research has consistently demonstrated high rates of comorbidity between OUD and psychiatric disorders, including major depressive disorder (MDD), generalized anxiety disorder (GAD), posttraumatic stress disorder (PTSD),

and personality disorders. This intersection is not coincidental; it is rooted in shared neurobiological vulnerabilities, overlapping psychosocial risk factors, and reciprocal interactions that reinforce both disorders over time. Psychologists, particularly those working in integrated or behavioral health settings, must understand how these conditions interact to deliver trauma-informed, evidence-based care.

Clients with OUD frequently present to treatment settings with a primary concern of psychological distress, such as hopelessness, emotional dysregulation, or suicidality, rather than substance use. In many cases, opioid misuse has emerged as a form of self-medication, a maladaptive strategy to manage painful affect, trauma symptoms, or chronic anxiety. Conversely, prolonged opioid use can exacerbate or even induce psychiatric symptoms by altering neurochemical function, impairing interpersonal functioning, and increasing social isolation. The bidirectional nature of this relationship complicates diagnosis, necessitating careful longitudinal assessment and a nuanced understanding of how one condition may mask or mimic the other.

Epidemiology and Clinical Significance of Comorbidity

Large-scale epidemiological studies have revealed that between 43% and 64% of individuals with OUD also meet criteria for a co-occurring mental health disorder (Han et al., 2020). Depression and anxiety are among the most frequently observed, followed closely by PTSD and bipolar disorder. Notably, the presence of psychiatric comorbidity is associated with more severe substance use, increased risk of overdose, lower treatment adherence, and poorer long-term outcomes (Volkow et al., 2016). Among individuals with both PTSD and OUD, rates of relapse are significantly higher compared to those with OUD alone, and traditional

abstinence-only approaches often fail unless trauma is also addressed in treatment.

In addition to affecting individual prognosis, comorbidity places additional strain on healthcare systems. Individuals with co-occurring disorders (CODs) have higher rates of emergency department utilization, psychiatric hospitalization, and criminal justice involvement. They often require more intensive and longer-term interventions, including medication-assisted treatment (MAT), psychotherapy, peer support, and case management. For psychologists, this underscores the necessity of working within interdisciplinary teams and advocating for holistic, coordinated care models.

Understanding why opioid use disorder frequently co-occurs with mental health disorders requires attention to shared neurobiological vulnerabilities, developmental risk factors, and the reciprocal relationship between emotional dysregulation and substance use. From a neurobiological perspective, chronic opioid exposure alters reward circuitry, stress response systems, and executive functioning networks, particularly within the mesolimbic dopamine pathway and prefrontal cortex. These same neural systems are implicated in mood and anxiety disorders, creating bidirectional vulnerability. Individuals with preexisting depression, PTSD, or bipolar disorder may use opioids as a form of self-medication to dampen hyperarousal, intrusive symptoms, emotional pain, or anhedonia. Conversely, prolonged opioid misuse can exacerbate depressive symptoms, increase anxiety sensitivity, and destabilize mood regulation through neuroadaptive changes and withdrawal cycles. Trauma exposure further compounds risk, as dysregulated stress physiology and impaired affect tolerance may drive repeated opioid use as a short-term coping mechanism. Clinically, this reinforces the principle that substance use and psychiatric symptoms are often functionally intertwined rather than independent conditions that coincidentally co-occur.

Integrated treatment models that address both opioid use disorder and co-occurring psychiatric conditions concurrently are consistently associated with improved retention and reduced relapse compared to sequential or parallel approaches. Psychologists should conduct comprehensive biopsychosocial assessments that explore temporal sequencing of symptoms, trauma history, suicidality risk, sleep disturbance, and cognitive impairment. Evidence-based interventions such as cognitive behavioral therapy for substance use disorders, trauma-focused therapies when clinically appropriate, and medication-assisted treatment should be coordinated rather than used separately. Measurement-based care practices, including routine monitoring of mood, urges and trigger intensity, trauma symptoms, and functional impairment, allow clinicians to adjust treatment responsively. Collaboration with prescribers, case managers, and peer recovery specialists is essential to reduce division of care.

Depression and Opioid Use Disorder

Major depressive disorder is one of the most common psychiatric comorbidities in individuals with OUD. Depression may precede opioid use, emerge during active use, or persist in recovery. Opioids exert mood-altering effects by increasing dopamine and endogenous opioids like beta-endorphins, producing temporary relief from depressive symptoms. However, this relief is short-lived, and chronic use leads to neuroadaptations that blunt natural reward pathways, exacerbating anhedonia and hopelessness.

Psychologists should be aware that clients with depression and OUD are at elevated risk for suicidal ideation and attempts. In fact, studies suggest that the co-occurrence of OUD and depression multiplies suicide risk severalfold (Ilgen et al., 2016). Furthermore, depression can reduce motivation for treatment, interfere

with cognitive processing in therapy, and heighten negative self-evaluation, all of which impact clinical outcomes.

Assessment tools such as the Patient Health Questionnaire-9 (PHQ-9) and the Beck Depression Inventory-II (BDI-II) can be used to screen for depressive symptoms. However, care must be taken to distinguish between opioid withdrawal effects and core depressive features. Withdrawal symptoms like fatigue, dysphoria, and sleep disturbance can mimic depression but may resolve after detoxification. Therefore, a longitudinal approach to assessment, ideally conducted after stabilization on MAT, is recommended.

Cognitive-behavioral therapy (CBT) remains a cornerstone for treating co-occurring depression and OUD. Emerging research also supports behavioral activation, mindfulness-based cognitive therapy (MBCT), and integrated treatments that combine MAT with psychotherapy. For example, clients receiving buprenorphine often experience mood stabilization, which can increase engagement in therapy and support sustained recovery.

Anxiety Disorders and Opioid Use

Anxiety disorders, including generalized anxiety disorder, panic disorder, and social anxiety disorder, frequently co-occur with OUD. Many individuals report using opioids to “take the edge off” anxious feelings or to cope with social situations they find overwhelming. This use can quickly escalate as tolerance develops, and the anxiolytic effects of opioids diminish. Moreover, opioid withdrawal often produces heightened autonomic arousal, such as restlessness, tachycardia, and gastrointestinal distress, which can resemble or trigger panic attacks in vulnerable individuals.

The interplay between anxiety and OUD is often overlooked, especially when anxiety is viewed solely as a symptom of withdrawal. However, longitudinal

studies have shown that untreated anxiety disorders increase the risk of opioid misuse, treatment dropout, and relapse (Back et al., 2018). Consequently, integrated treatment approaches that address both anxiety and substance use simultaneously yield better outcomes than sequential or siloed care.

Psychologists should utilize screening instruments such as the Generalized Anxiety Disorder-7 (GAD-7), the Panic Disorder Severity Scale (PDSS), and structured clinical interviews to assess the presence and severity of anxiety symptoms. Exposure-based therapies, including prolonged exposure and acceptance and commitment therapy (ACT), have demonstrated efficacy in treating comorbid anxiety and OUD. However, these interventions should be adapted to consider the client's stage of change, level of emotional regulation, and substance use patterns.

Pharmacotherapy may also play a role in the treatment of anxiety and OUD, but caution is warranted. Benzodiazepines, commonly prescribed for anxiety, carry a high risk of dependency and can be lethal when combined with opioids. Psychologists should collaborate with prescribers to ensure that clients receive safe, evidence-based medications, such as SSRIs or buspirone, when appropriate.

Trauma and PTSD in the Context of OUD

Among all psychiatric conditions comorbid with OUD, PTSD presents some of the most complex challenges. A significant proportion of individuals with OUD have experienced physical, sexual, or emotional trauma, often beginning in childhood. The Adverse Childhood Experiences (ACE) study revealed a strong, graded relationship between childhood trauma and adult opioid misuse, with individuals reporting four or more ACEs at significantly elevated risk for both initiation and escalation of use (Felitti et al., 1998; Bohnert et al., 2019).

Trauma and opioid misuse interact through multiple pathways. Some individuals use opioids to numb emotional pain or intrusive memories, while others develop

PTSD following trauma sustained during the course of substance use, such as sexual assault or violence. Chronic exposure to trauma can dysregulate the hypothalamic-pituitary-adrenal (HPA) axis and impair emotion regulation, increasing vulnerability to both PTSD and addiction.

Clients with comorbid PTSD and OUD often display hypervigilance, dissociation, emotional numbing, and heightened reactivity. These symptoms can interfere with the therapeutic alliance, trigger mistrust, or lead to early dropout. Therefore, trauma-informed care is essential in both assessment and intervention. This approach prioritizes safety, transparency, collaboration, and choice, and seeks to empower clients by validating their experiences and responses to adversity.

Screening for trauma and PTSD should be conducted using validated tools such as the PTSD Checklist for DSM-5 (PCL-5), the Life Events Checklist, or the Clinician-Administered PTSD Scale (CAPS-5). In addition, clinicians should assess for dissociation, moral injury, and complex trauma—dimensions not always captured by standard PTSD measures but relevant to many individuals with severe OUD.

Integrated treatment models that simultaneously address PTSD and substance use have shown promising results. Approaches such as Seeking Safety, Trauma Recovery and Empowerment Model (TREM), and cognitive processing therapy (CPT) modified for addiction are increasingly supported by empirical research (Najavits, 2015). These interventions emphasize emotion regulation, cognitive restructuring, and safe processing of traumatic memories while minimizing risk of destabilization.

Integrated and Collaborative Care Models

Historically, the treatment of mental health and substance use disorders occurred in parallel systems, often with conflicting philosophies and goals. Clients with co-occurring disorders were frequently excluded from care or bounced between

providers. Today, the movement toward integrated care seeks to dismantle these silos by embedding mental health services within addiction treatment and vice versa. Psychologists are central to this shift, offering diagnostic expertise, psychotherapy, behavioral consultation, and team-based collaboration.

Integrated care models range from co-located services (where mental health and addiction providers work in the same facility) to fully integrated systems in which interdisciplinary teams share treatment plans and coordinate care across disciplines. These models have demonstrated improved outcomes in retention, symptom reduction, and client satisfaction, especially for individuals with high comorbidity and complex needs (SAMHSA, 2022).

Psychologists working in integrated care must be flexible, collaborative, and competent in both mental health and addiction sciences. They must also be attuned to ethical concerns, including confidentiality in team settings, role clarity, and the potential for dual relationships. Effective communication, shared documentation, and cross-training among team members are critical for success.

Technology also plays a role in expanding access to integrated care. Telepsychology and digital interventions can reach clients in rural or underserved areas and offer tools for symptom monitoring, psychoeducation, and skill-building. Apps such as reSET-O and CBT4CBT have been tested in clients with OUD and show potential for reducing cravings and improving engagement.

Special Considerations for Suicide Risk

Suicide risk is a critical concern in individuals with co-occurring OUD and mental health disorders. The National Survey on Drug Use and Health (NSDUH) reports that people with OUD are significantly more likely to experience suicidal ideation, make suicide plans, and attempt suicide than those without substance use

disorders. Risk is highest among those with concurrent depression, trauma, or personality disorders.

Psychologists must conduct thorough, culturally competent suicide risk assessments that consider both acute and chronic risk factors. Tools such as the Columbia-Suicide Severity Rating Scale (C-SSRS) and the Suicide Assessment Five-Step Evaluation and Triage (SAFE-T) can provide structured guidance. Assessments should also address access to means (especially opioids), previous attempts, hopelessness, impulsivity, and protective factors.

Safety planning, brief cognitive interventions for suicide, and collaborative documentation are essential elements of suicide prevention in this population. Clinicians should also be aware of the risks associated with post-discharge periods from detoxification or inpatient care, which are times of heightened suicide risk due to reduced tolerance and psychological distress.

Section 4: Evidence-Based Psychosocial Interventions and Collaborative Care Approaches for Opioid Use Disorder

Introduction

Psychosocial interventions are central to the comprehensive treatment of opioid use disorder (OUD). While pharmacological treatments such as methadone, buprenorphine, and naltrexone form the foundation of medical management, these medications are most effective when combined with structured, evidence-based psychosocial support. Research consistently demonstrates that individuals who receive integrated behavioral and pharmacologic interventions have better

treatment retention, reduced relapse rates, improved psychosocial functioning, and enhanced quality of life (Bergman et al., 2019; Zerden et al., 2020).

Psychologists are at the forefront of delivering and adapting these interventions across diverse treatment settings, including outpatient mental health clinics, primary care offices, substance use treatment facilities, and community-based programs. This section explores the most widely supported psychosocial interventions, including cognitive behavioral therapy (CBT), motivational interviewing (MI), contingency management (CM), and mindfulness-based interventions, as well as collaborative care models that promote interdisciplinary integration. Emphasis is placed on interventions supported by empirical evidence, particularly those validated in diverse populations and community settings.

Cognitive Behavioral Therapy (CBT)

CBT is among the most thoroughly researched and widely implemented psychosocial treatments for OUD. This structured, time-limited, and skills-based intervention targets the maladaptive thoughts and behaviors that contribute to substance use and relapse. CBT for OUD typically focuses on developing coping skills, managing cravings, restructuring cognitive distortions, identifying triggers, and planning for high-risk situations.

Empirical studies have found CBT to be effective both as a standalone therapy and as an adjunct to medication-assisted treatment (MAT). In randomized trials, clients receiving CBT alongside buprenorphine demonstrated significantly greater reductions in illicit opioid use compared to those receiving medication alone (Witkiewitz et al., 2023). Importantly, CBT also improves psychological distress, enhances self-efficacy, and reduces comorbid symptoms of anxiety and depression, which are common among individuals with OUD.

In clinical practice, CBT for opioid use disorder often begins with functional analysis to help clients identify the specific thoughts, emotions, environmental cues, and physiological states that precede opioid use. For example, a client maintained on buprenorphine may report recurrent cravings in the late afternoon after work. Through structured cognitive and behavioral foundations, the clinician and client might identify triggers such as physical fatigue, unresolved work stress, and automatic thoughts such as “I cannot relax without using” or “One pill will not affect me.” The clinician then guides cognitive restructuring by examining evidence for and against these beliefs, generating alternative coping statements such as “Cravings peak and pass” or “Using once increases risk of relapse.” Behavioral rehearsal is incorporated through in-session role-play of high-risk scenarios, such as encountering a former dealer or being offered opioids by a peer. Clients are taught mindfulness techniques, stimulus control strategies, and behavioral activation planning, including scheduling structured activities during vulnerable times. Homework assignments may include craving logs, thought records, and implementation of alternative coping behaviors such as brief exercise, distress tolerance exercises, or contacting a recovery support person.

CBT also frequently integrates relapse prevention planning that is concrete, personalized, and forward-looking. Clinicians work collaboratively with clients to develop a written relapse prevention plan that identifies early warning signs, internal triggers, external high-risk environments, and protective supports. Behavioral experiments may be assigned, such as attending a social event without substance use and tracking anxiety reduction over time to increase self-efficacy. Throughout treatment, clinicians use measurement-based care practices, including standardized craving scales and mood assessments, to monitor progress and adjust interventions accordingly. These practical applications ensure that CBT for opioid use disorder remains structured, collaborative, and integrated with medication-assisted treatment and broader recovery planning.

Adaptations of CBT for OUD have been created to meet the needs of specific populations. For example, group-based CBT models have been shown to be effective for women with histories of trauma, while culturally tailored CBT interventions have improved outcomes among racial and ethnic minorities (Peter et al., 2023). Moreover, digital CBT programs, such as CBT4CBT, have emerged as viable tools for expanding access to evidence-based care in rural or underserved regions (Scialanca et al., 2025).

Motivational Interviewing (MI)

Motivational interviewing is a client-centered, directive approach designed to enhance intrinsic motivation for change. Originally developed for alcohol use disorders, MI has been widely applied to the treatment of opioid misuse and is now considered a standard component of most evidence-based SUD protocols.

MI is practically integrated into ongoing opioid use disorder treatment to strengthen adherence and reduce dropout. For instance, when a client misses MAT appointments, instead of framing the lapse as noncompliance, the psychologist might explore discrepancies between stated recovery goals and current behaviors using techniques such as decisional balance exercises. A structured discussion may involve listing perceived benefits of continued opioid use alongside costs, then comparing these with the client's stated long-term values such as parenting, employment stability, or health. Scaling questions, such as "On a scale from 0 to 10, how ready are you to reduce your use?" followed by "Why not a lower number?" elicit change-oriented statements. In criminal justice or mandated treatment contexts, MI can help shift external motivation toward internalized reasons for recovery by focusing on personal goals rather than legal consequences alone. Throughout treatment, psychologists maintain fidelity to MI principles by avoiding directive persuasion, excessive advice-giving, or

argumentation. Instead, they evoke clients' own motivations and reinforce self-efficacy, recognizing that sustained recovery from opioid use disorder is more likely when individuals experience agency, collaboration, and respect within the therapeutic relationship.

MI is particularly valuable during the early stages of treatment, when clients may be ambivalent about stopping opioid use. Through open-ended questions, affirmations, reflective listening, and strategic summaries, psychologists using MI help clients resolve ambivalence and strengthen their commitment to change. The focus is on collaboration rather than confrontation, with an emphasis on client autonomy and empowerment.

Meta-analyses have demonstrated that MI is effective in increasing treatment engagement, promoting retention in MAT, and reducing illicit drug use among individuals with OUD (Durpoix et al., 2024). Moreover, MI's flexibility allows it to be integrated into brief interventions in primary care, emergency departments, and criminal justice settings. Combined with personalized feedback and goal setting, MI can foster insight and readiness for longer-term behavioral treatment.

Psychologists using MI must be trained in the method's nuanced communication style and must avoid the trap of trying to persuade or "fix" clients. When delivered with fidelity, MI increases self-efficacy and reduces resistance, factors that strongly predict long-term recovery success. Throughout treatment, psychologists maintain fidelity to MI principles by avoiding directive persuasion, excessive advice-giving, or argumentation. Instead, they evoke clients' own motivations and reinforce self-efficacy, recognizing that sustained recovery from opioid use disorder is more likely when individuals experience agency, collaboration, and respect within the therapeutic relationship.

Contingency Management (CM)

Contingency management is a behavioral intervention that uses tangible rewards to reinforce abstinence and treatment adherence. Based on operant conditioning principles, CM typically involves providing clients with incentives (e.g., vouchers, prizes, or privileges) contingent upon verified drug-free urine screens or consistent attendance.

CM has amassed a strong body of evidence in the treatment of OUD, particularly when used in combination with MAT. Studies have shown that CM improves treatment retention, reduces opioid and cocaine use, and promotes medication adherence (Murphy et al., 2023). Importantly, CM is effective across a wide range of settings, including outpatient clinics, community health centers, and justice-involved populations.

A common concern regarding CM is its perceived cost and logistical complexity. However, studies have found that the intervention is cost-effective when considering reductions in emergency care, hospitalization, and criminal justice involvement (Haibach et al., 2014). CM is especially beneficial for high-risk populations, including individuals experiencing homelessness, those with co-occurring mental illness, and adolescents with early-onset opioid misuse.

In applied clinical settings, contingency management is typically implemented through structured reinforcement schedules that are clearly explained at the outset of treatment. For example, a client receiving buprenorphine for opioid use disorder may earn vouchers of increasing monetary value for each consecutive opioid-negative urine drug screen. If a screen is positive or missed, the reinforcement schedule may reset to the initial value, thereby reinforcing sustained abstinence. These practical applications align with behavioral learning principles and demonstrate how immediate, consistent reinforcement can counteract the powerful reward conditioning associated with opioid use.

Effective implementation requires clear protocols, objective verification methods, and consistent delivery to maintain treatment integrity. Psychologists must ensure that reinforcement criteria are transparent, measurable, and ethically administered without coercion. Cultural sensitivity is also critical; incentives must be relevant and respectful of community context. For adolescents or young adults with early-onset opioid misuse, small but frequent rewards for attendance and skill completion may enhance engagement, while for individuals with co-occurring mental illness, reinforcement schedules may initially target medication adherence or therapy participation before full abstinence goals are achieved. Hybrid models can also incorporate social reinforcement, such as public recognition within group therapy, recovery milestone certificates, or peer acknowledgment, which strengthen intrinsic motivation alongside tangible rewards. When implemented with fidelity and integrated with medication-assisted treatment and psychosocial care, contingency management supports retention, promotes behavioral stabilization, and enhances overall recovery trajectories in opioid use disorder treatment.

For psychologists, implementing CM requires careful planning, ethical oversight, and cultural sensitivity. Incentives must be meaningful to the target population and delivered consistently. While not all programs can implement full-scale CM, hybrid models using social reinforcement or peer recognition may still produce positive behavioral effects.

Mindfulness-Based and Acceptance Approaches

In recent years, mindfulness-based interventions (MBIs), including mindfulness-based relapse prevention (MBRP) and acceptance and commitment therapy (ACT), have gained empirical support as complementary treatments for OUD. These

approaches focus on increasing present-moment awareness, reducing experiential avoidance, and cultivating psychological flexibility.

Clients with OUD often experience intense craving, emotional reactivity, and difficulty tolerating distress, all of which are addressed through mindfulness practices. MBRP integrates mindfulness meditation with relapse prevention skills, teaching clients to observe urges without acting on them. In applied treatment settings, mindfulness-based relapse prevention and acceptance and commitment therapy are often delivered through structured, experiential exercises that directly address real-world opioid triggers. For example, during a high-risk situation rehearsal, a psychologist might guide a client through a "STOP" practice: stop, take a breath, observe internal experience, and proceed with intention. A client who reports craving opioids after conflict with a partner may be coached to pause, identify the surge of anger and craving as temporary internal states, and choose a response aligned with long-term recovery goals rather than acting impulsively. Clients are also encouraged to use brief daily mindfulness check-ins, such as three-minute breathing spaces before taking prescribed medication, to strengthen awareness and reduce automaticity. These structured practices increase distress tolerance and interrupt habitual substance use patterns by creating space between urge and action.

ACT, on the other hand, emphasizes values clarification and committed action, helping clients to live a meaningful life even in the presence of difficult internal experiences. In ACT-based applications, practical exercises frequently include values card sorts, written values statements, and committed action planning. When intrusive thoughts arise, such as "I will never stay sober," the psychologist may introduce cognitive diffusion techniques like repeating the thought slowly until it loses emotional intensity. Homework assignments may include mindfulness logs tracking cravings and emotional triggers, alongside reflection on whether daily actions align with identified values. Through these practical applications,

mindfulness-based interventions move beyond abstract concepts and become structured, skills-based components of comprehensive opioid use disorder treatment that support sustained behavioral change and recovery maintenance.

Research has shown that MBIs can reduce substance use, cravings, and stress while improving emotional regulation and quality of life (Dellazizzo et al., 2023). MBIs are also perceived as less stigmatizing by clients, particularly those who have had negative experiences with traditional abstinence-based programs. For psychologists trained in these approaches, MBIs offer a powerful addition to the therapeutic toolkit, particularly for clients with trauma histories or chronic emotion dysregulation.

Collaborative and Integrated Care Models

Collaborative care refers to models in which medical, behavioral, and support services are coordinated across disciplines to provide comprehensive care for individuals with complex needs. In the context of OUD, collaborative care has become a gold standard, especially in primary care, behavioral health homes, and federally qualified health centers.

Psychologists play a key role in collaborative care teams, contributing expertise in behavioral assessment, motivational strategies, care planning, and psychotherapy. In integrated models, psychologists may co-manage cases with physicians, nurse practitioners, social workers, and peer recovery coaches. Shared decision-making and a unified care plan ensure that clients receive coherent and consistent services.

Evidence supports the effectiveness of collaborative care in improving OUD outcomes. Zerden et al. (2020) found that office-based opioid treatment (OBOT) programs that included behavioral health integration had higher rates of medication adherence, lower relapse rates, and increased client satisfaction.

Collaborative care also enhances screening for co-occurring disorders, facilitates warm handoffs between providers, and supports long-term recovery maintenance.

Effective collaborative care requires psychologists to engage in regular interdisciplinary communication, participate in case conferences, and document care in shared electronic health records. Challenges may include navigating differing treatment philosophies, role confusion, and reimbursement constraints. Nevertheless, the benefits of holistic care far outweigh the logistical hurdles.

Technology-Enhanced Interventions

Technology is rapidly reshaping how psychosocial interventions are delivered for OUD. Digital tools, including mobile apps, online therapy platforms, and telehealth, offer new pathways for engagement, especially among younger clients and those in geographically remote areas.

CBT-based digital programs such as CBT4CBT, reSET-O, and Pear Therapeutics' digital therapeutics have been approved by the FDA and integrated into some MAT programs (Scialanca et al., 2025). These tools deliver structured content on coping strategies, behavioral activation, and relapse prevention, often with interactive components and clinician dashboards for monitoring progress.

Text messaging interventions, online peer support groups, and virtual recovery coaching also show promise in extending psychosocial support outside of clinical hours. For example, Just-in-Time Adaptive Interventions (JITAIs) use ecological momentary assessments to detect relapse risk in real time and deliver supportive messages or prompts to engage in healthy behaviors.

Psychologists incorporating digital tools must assess client access, digital literacy, and privacy considerations. While technology cannot replace human relationships,

it can enhance continuity of care and provide critical support during high-risk moments.

Adapting Interventions for Special Populations

Evidence-based psychosocial interventions must be adapted to meet the unique needs of specific populations affected by OUD, including adolescents, women, veterans, LGBTQ+ individuals, and communities of color.

For example, adolescent-focused interventions often incorporate family therapy, school engagement, and peer-based support. Motivational interviewing combined with contingency management has shown success among youth, especially when delivered in juvenile justice or school-based settings (Welsh et al., 2020).

For women with OUD, trauma-informed care is essential. Many female clients have experienced intimate partner violence, reproductive coercion, or trauma related to child custody. Integrating CBT with trauma recovery models such as Seeking Safety enhances outcomes in these cases (Najavits, 2015).

Veterans and first responders may benefit from ACT or prolonged exposure combined with MAT, given high rates of PTSD. Culturally responsive adaptations of MI and CBT can also address structural racism, stigma, and historical trauma in marginalized communities.

Psychologists must also consider language access, literacy levels, and spiritual or community values when tailoring interventions. Flexibility, humility, and collaboration with community stakeholders are crucial for success.

Ethical and Practical Considerations

Delivering psychosocial interventions for OUD requires careful attention to ethics, boundaries, and systemic issues. Psychologists must navigate confidentiality in team-based care, avoid dual relationships, and remain aware of personal biases and countertransference when working with individuals with addiction.

Informed consent should include a discussion of nature, risks, and benefits of treatment options, including potential medication side effects and the role of behavioral therapies. Treatment plans should be collaborative, recovery-oriented, and grounded in cultural humility.

Additionally, psychologists should advocate for systemic changes, including expanded access to MAT, reduced stigma, and integration of behavioral health into primary care and community settings. Their role as scientist-practitioners positions them to influence policy, develop training, and contribute to the evolving landscape of addiction treatment.

Section 5: Risk Factors, Overdose Prevention, and Harm Reduction Strategies

Understanding Risk in the Opioid Landscape

The opioid epidemic remains one of the deadliest public health crises in recent history, with opioid-involved overdoses continuing to drive morbidity and mortality rates across the United States and globally. In 2023 alone, over 80,000 Americans lost their lives due to opioid-related overdose, with synthetic opioids such as fentanyl responsible for the majority of fatalities (CDC, 2024). This escalating crisis highlights the urgent need for mental health professionals, particularly psychologists, to understand not only the clinical presentation of

opioid use disorder (OUD), but also the multifactorial risk dynamics that contribute to misuse and overdose. The factors involved in opioid misuse are cumulative, complex, and highly contextual, encompassing biological predispositions, trauma exposure, mental health conditions, socioeconomic pressures, and systemic barriers to care.

Risk is not uniformly distributed across the population. Structural inequities mean that communities of color, people experiencing homelessness, individuals involved in the criminal justice system, and those with co-occurring psychiatric conditions often face higher odds of both developing OUD and dying from an overdose. Thus, overdose prevention and harm reduction efforts must be culturally responsive, community-driven, and rooted in the principles of health equity and trauma-informed care. Psychologists are uniquely positioned to identify at-risk individuals, implement evidence-based prevention strategies, and collaborate with multidisciplinary teams to advance harm reduction in clinical and community settings.

Individual and Sociodemographic Risk Factors

Several individual-level factors have been identified as increasing vulnerability to opioid misuse and overdose. These include a personal or family history of substance use disorders, early exposure to opioids (either prescribed or illicit), chronic pain conditions, and untreated mental illness. Genetic predisposition plays a role, as does neurobiological sensitivity to opioids, particularly in those with dysregulated reward systems or histories of adverse childhood experiences (ACEs) (Felitti et al., 1998).

Mental health disorders significantly elevate overdose risk. Depression, anxiety, PTSD, and borderline personality disorder are all highly comorbid with OUD and are often underdiagnosed or undertreated in populations most affected by opioid

misuse (Bohnert et al., 2019). These disorders increase impulsivity, hopelessness, and emotional dysregulation, which in turn drive higher rates of substance use and suicide attempts. Furthermore, individuals with dual diagnoses often face fragmented care systems where mental health and substance use services operate in isolation, increasing their risk of falling through the cracks.

Sociodemographic variables such as poverty, unemployment, housing instability, and lack of access to healthcare are also key drivers of opioid-related harms. Kalicum et al. (2025) noted that people experiencing homelessness are disproportionately impacted by overdose, with high rates of poly-substance use, limited access to naloxone, and barriers to consistent care. Racial disparities also persist, particularly as synthetic opioids have penetrated urban and low-income communities. Black Americans have seen sharp increases in overdose deaths yet continue to receive fewer referrals to treatment and naloxone prescriptions than their White counterparts (Kennedy et al., 2024).

Clinical and Systemic Risk Pathways

In addition to individual and structural risk factors, certain clinical and systemic dynamics increase the likelihood of overdose. One such factor is prior incarceration. Upon release from prison or jail, individuals often experience a dramatic drop in opioid tolerance. Without access to continuity of care or MAT, even a previously tolerated dose can become fatal. The weeks following incarceration are among the most high-risk periods for overdose death, underscoring the need for pre-release planning and linkage to community services (Binswanger et al., 2018).

Similarly, periods following medical detoxification or inpatient treatment are particularly dangerous. Clients may leave structured care with reduced tolerance but persistent cravings. If they relapse, often due to unresolved trauma,

inadequate psychosocial support, or insufficient transition planning, they are at significant risk for overdose. Psychologists can help mitigate this risk by facilitating warm handoffs, safety planning, and ongoing monitoring during these vulnerable transitions.

Another critical issue is poly-substance use. Many opioid-involved overdoses also involve benzodiazepines, alcohol, or stimulants such as cocaine and methamphetamine. The combination of central nervous system depressants (e.g., opioids and benzos) drastically increases the risk of respiratory depression and death. Clinicians must assess not only for opioid use, but for the full range of substances that may be used simultaneously or sequentially. Clients often underreport secondary substances, particularly if they believe those substances are less stigmatized or not the “focus” of treatment.

Suicide and Intentional Overdose

Suicide is an underrecognized dimension of the opioid overdose crisis. While many overdoses are accidental, a significant portion are intentional or reflect ambiguous intent, particularly among individuals with chronic pain, trauma, and untreated psychiatric illness. Studies have shown that individuals with OUD are 14 times more likely to die by suicide than the general population (Ilgen et al., 2016). For clients with histories of trauma or loss, opioids may serve as both a means of escape and a mechanism of self-harm.

Psychologists must conduct thorough, culturally sensitive assessments of suicidal ideation and intent in individuals who misuse opioids. Risk assessments should explore not only overt suicidality, but also passive death wishes, reckless behavior, and hopelessness. The use of structured tools such as the Columbia-Suicide Severity Rating Scale (C-SSRS) can assist in standardizing assessments, but clinical judgment and rapport remain essential. Collaborative safety planning, crisis

response protocols, and continuity of care are crucial components of suicide prevention in this population.

In clinical practice, suicidal intent among individuals with opioid use disorder may present in nuanced and ambiguous ways that require careful assessment beyond direct questions about intent to die, or assessment screeners. For example, a client experiencing severe withdrawal and hopelessness may report intentionally taking higher-than-prescribed doses of opioids “just to knock myself out” or combining opioids with alcohol or benzodiazepines despite awareness of the heightened overdose risk. Others may describe escalating use during periods of interpersonal loss or trauma exposure while stating, “I just want the pain to stop,” without explicitly endorsing suicidal intent. Psychologists must differentiate between accidental overdose risk, passive self-harm behaviors, and active suicidal planning, recognizing that intent can fluctuate rapidly.

A culturally responsive suicide risk assessment should explore frequency, intensity, and duration of suicidal thoughts; access to lethal means; recent increases in substance use; and patterns of impulsivity. Structured tools such as the Columbia-Suicide Severity Rating Scale can enhance standardization, but assessment should also include open-ended inquiry about meaning, shame, stigma, and perceived burdensomeness. Clinical judgment, careful documentation, and ongoing monitoring are essential, particularly during high-risk periods such as early recovery, medication transitions, or relapse episodes.

Equally important is the systematic evaluation of protective factors, which provide balance and guide intervention planning. Protective elements may include supportive family or peer relationships, engagement in medication for opioid use disorder, stable housing, spiritual or cultural beliefs discouraging self-harm, future-oriented goals, and active participation in psychotherapy. Clients who are consistently attending MAT appointments, maintaining therapeutic alliances, or

expressing commitment to caregiving roles, such as “I am a responsible mother”, may demonstrate resilience even in the presence of suicidal ideation. Collaborative safety planning should incorporate these protective factors by identifying specific individuals to contact, safe environments, coping strategies for acute craving or despair, and removal or restriction of lethal means when feasible. Continuity of care, including warm handoffs between emergency departments, outpatient providers, and addiction specialists, further strengthens safety. Documentation and consultation are critical components to substance use treatment and suicidal ideation interventions.

Overdose Prevention Strategies

Effective overdose prevention involves a multifaceted approach combining behavioral interventions, pharmacologic support, education, and system-level coordination. One of the most powerful tools in overdose prevention is naloxone (Narcan), an opioid antagonist that reverses the effects of opioid overdose and restores normal respiration. Naloxone is safe, easy to administer, and effective within minutes. It is available in both intranasal and injectable forms, and can be administered by laypersons, first responders, or clinicians.

Psychologists should be trained in naloxone administration and advocate for widespread access, particularly for clients at elevated risk. This includes clients with recent detoxification, co-occurring mental illness, poly-substance use, and those exiting correctional facilities. Moreover, psychologists can play a key role in destigmatizing naloxone by incorporating overdose education into therapy sessions and discussing it as a life-saving safety net, not as a sign of treatment failure.

Programs that distribute naloxone to clients, family members, and community members have been shown to significantly reduce overdose deaths. Community-

based initiatives, such as overdose prevention sites (OPS) and syringe service programs (SSPs), offer not only naloxone but also safer use education, referrals to treatment, and medical care. These programs reduce the transmission of HIV and hepatitis C, increase engagement in care, and serve as low-barrier entry points to services for highly marginalized individuals.

Harm Reduction as a Public Health Framework

Harm reduction is a set of practical strategies and ideas aimed at minimizing negative consequences of drug use without necessarily requiring abstinence. It includes needle exchange, supervised consumption spaces, fentanyl test strips, naloxone distribution, and safer use education. At its core, harm reduction is rooted in principles of human rights, dignity, and compassion. It recognizes that drug use occurs across a spectrum and seeks to meet individuals where they are.

For psychologists, integrating harm reduction into practice requires a shift from punitive or abstinence-only frameworks toward a more person-centered, collaborative, and flexible approach. It means respecting client autonomy, acknowledging their lived expertise, and focusing on incremental progress rather than all-or-nothing outcomes. This is particularly important when working with clients who have experienced criminalization, medical trauma, or coercive treatment environments.

Harm reduction is supported by a growing body of empirical evidence. For example, studies of supervised consumption sites in Canada, Australia, and parts of the U.S. have demonstrated reductions in overdose mortality, increased referrals to treatment, and decreased public drug use (Kennedy et al., 2024). Fentanyl test strip programs help clients identify contaminated drug supplies and make informed decisions, reducing the risk of fatal overdose.

Psychologists can incorporate harm reduction into their work in multiple ways: discussing safer use strategies, advocating for naloxone distribution, supporting client-defined goals, and collaborating with community programs. While some psychologists may work in settings that emphasize abstinence, harm reduction principles can still guide therapeutic stance, language, and engagement strategies.

Harm Reduction and Trauma-Informed Care

The overlap between harm reduction and trauma-informed care is substantial. Both frameworks emphasize safety, choice, collaboration, and respect for autonomy. Clients with OUD often have complex trauma histories, and rigid or judgmental approaches may replicate past power dynamics or exacerbate shame. Trauma-informed harm reduction recognizes that substance use is often a coping strategy for overwhelming emotional pain and prioritizes relational safety over compliance.

Incorporating trauma-informed harm reduction means avoiding confrontational interventions, using inclusive language, and creating non-coercive spaces for change. It also means attending to basic needs, such as food, housing, or safety, which may be more pressing than immediate abstinence. For psychologists, this can include working with case managers, supporting harm reduction goals within a broader care plan, and validating ambivalence or fears about change.

Programs such as Housing First, which provides permanent housing without preconditions of sobriety, have been shown to reduce overdose deaths and improve quality of life among people who use opioids. These programs exemplify how harm reduction can be applied at the structural level to address root causes of substance use and instability.

Ethical Considerations in Harm Reduction

Ethical practice in overdose prevention and harm reduction requires navigating tensions between client autonomy, public safety, and professional values. Psychologists may encounter dilemmas related to client use within treatment, differing philosophies among team members, or institutional policies that restrict harm reduction approaches.

The APA Ethical Principles of Psychologists and Code of Conduct emphasize beneficence, nonmaleficence, and respect for individuals' rights and dignity. These principles align well with harm reduction, which prioritizes reducing harm even when abstinence is not immediately achievable. Psychologists must also be mindful of confidentiality, especially when discussing overdose risk or collaborating with other providers. Informed consent, shared decision-making, and cultural humility are key to ethical harm reduction practice.

Clinicians working with minors, pregnant individuals, or those involved in legal systems may face additional complexities. State laws vary regarding parental consent, mandated reporting, and medication access. Psychologists should familiarize themselves with relevant policies, seek supervision when appropriate, and center their work on the best interests and stated goals of the client.

Section 6: Ethical Considerations, Cultural Competence, and Communication Strategies in Working with Clients Using Opioids

Introduction

The opioid epidemic poses an urgent ethical and professional challenge for psychologists and mental health professionals. As frontline providers working with individuals affected by opioid use disorder (OUD), psychologists must navigate a complex landscape of ethical decision-making, cultural diversity, and effective therapeutic communication. This section explores the intersection of ethics, cultural competence, and communication within the context of psychological care for individuals with OUD. It highlights best practices and evidence-based guidance to promote ethical integrity, culturally responsive care, and respectful, trauma-informed communication strategies.

Ethical Responsibilities of Psychologists in Treating OUD

Psychologists are guided by the American Psychological Association's (APA) Ethical Principles of Psychologists and Code of Conduct (2017), which establish standards for competence, integrity, and beneficence. Within the context of OUD, these principles are especially relevant, as clients are often stigmatized, marginalized, and vulnerable to systemic inequities.

Competence is a critical consideration when treating individuals with substance use disorders. APA Ethical Standard 2.01 requires psychologists to practice within the boundaries of their competence, which includes understanding the biological, psychological, and social dimensions of OUD. As the science of addiction treatment evolves, psychologists must pursue continuing education to stay

abreast of emerging interventions, cultural considerations, and systemic issues affecting clients with OUD.

Confidentiality (Standard 4.01) presents nuanced challenges when working with clients involved in legal systems, child welfare, or healthcare coordination. Psychologists must balance client privacy with legal reporting obligations and interdisciplinary communication. Informed consent should include a discussion about limits of confidentiality and the potential implications of information-sharing across systems.

The principle of beneficence and nonmaleficence (Principle A) obligates psychologists to act in the best interest of the client while minimizing potential harm. Given the high-risk nature of opioid misuse, psychologists must assess for imminent risk (e.g., overdose, self-harm) and intervene accordingly, sometimes involving external entities or crisis services.

Justice (Principle D) compels psychologists to ensure equitable access to care and advocate for marginalized clients. This includes challenging policies or institutional practices that disproportionately affect people of color, low-income individuals, or those with co-occurring disorders.

Finally, respecting client autonomy while addressing potentially life-threatening behaviors demands ethical sensitivity and collaborative care. Clients with OUD often face stigma and may be wary of mental health services. Ethical practice requires empathy, transparency, and empowerment.

Cultural Competence in Treating Clients with OUD

Cultural competence is essential for providing effective and respectful care to individuals from diverse racial, ethnic, gender, and socioeconomic backgrounds. Psychologists must be able to recognize how social identities, historical trauma,

and structural inequalities shape clients' experiences with opioid use and treatment systems.

Cultural competence extends beyond knowledge of cultural norms; it requires self-awareness, humility, and a commitment to ongoing learning. Sue et al. (2019) emphasizes the importance of cultural humility, a lifelong process of critical self-reflection about one's own cultural assumptions and biases. In the context of OUD, cultural competence involves understanding the disproportionate burden of the epidemic on certain populations and adapting interventions accordingly.

For example, Indigenous communities in North America have experienced a rise in opioid-related mortality, compounded by the legacy of colonization and systemic neglect. Culturally responsive approaches in these settings often include incorporating traditional healing practices, working with tribal authorities, and recognizing historical trauma.

Similarly, Latinx and Black communities have historically been underdiagnosed with substance use disorders and overrepresented in the criminal justice system. The intersection of race and substance use requires psychologists to examine their own biases and advocate for equity in treatment, access and outcomes.

Immigrants and refugees may also experience unique barriers, including language differences, fear of deportation, and lack of culturally relevant services. Using interpreters, offering bilingual materials, and building rapport within cultural contexts are necessary adaptations.

Gender and sexual identity also intersect with opioid use in important ways. Transgender individuals face higher rates of substance use and lower access to affirming care. Cultural competence must include awareness of gender-affirming practices, avoiding misgendering, and ensuring psychological safety in therapy.

Rural populations may encounter geographic and cultural barriers to treatment, including stigma and lack of providers. In these contexts, telehealth may be a critical bridge, but psychologists must still ensure cultural attunement to local norms and community dynamics.

Ultimately, culturally competent care is trauma-informed, relational, and rooted in respect. It acknowledges the client as an expert in their own experience and centers their voice in the treatment process.

Addressing Stigma and Bias in Treatment

Stigma remains a pervasive barrier to care for individuals with OUD. Public and internalized stigma can deter clients from seeking help, contribute to feelings of shame, and impair therapeutic engagement. Psychologists must actively work to counter stigma both interpersonally and institutionally.

The language used in treatment and documentation matters significantly. Terms like “addict” or “substance abuser” carry judgmental connotations and reinforce moralistic views of substance use. Person-first language, such as “a person with opioid use disorder”, humanizes the client and aligns with APA guidance (Werder et al., 2022).

Implicit bias among providers can also influence clinical decisions, including risk assessment, diagnosis, and treatment planning. Research indicates that racial minorities are often perceived as more culpable and less deserving of care, even unconsciously (Burlew et al., 2017). Regular training, self-reflection, and consultation can help mitigate bias and promote equitable care.

Stigma may also manifest in policy-level barriers, such as punitive responses to relapses or restrictions on medications for opioid use disorder (MOUD). Psychologists can play a role in challenging these structural forms of stigma by

supporting harm reduction, advocating for policy reform, and promoting public education.

Therapeutic work should include validating the client's lived experience of stigma and exploring how it affects their self-image, relationships, and treatment engagement. Narrative therapy and strengths-based approaches can empower clients to reframe their identities beyond the label of "addict."

Ethical Communication in Interdisciplinary and Collaborative Settings

Effective care for OUD often involves collaboration with medical providers, social workers, peer support specialists, and criminal justice professionals. Psychologists must communicate ethically and effectively in these interdisciplinary settings.

Interprofessional communication requires clarity, respect for professional roles, and adherence to confidentiality laws such as HIPAA and 42 CFR Part 2, which provides additional privacy protections for substance use treatment records. Psychologists should ensure that releases of information are specific, time-limited, and fully understood by the client.

Case coordination meetings, particularly in integrated care or drug court settings, may challenge traditional confidentiality norms. Psychologists must advocate for their clients' rights while balancing public safety and treatment accountability. Transparency with clients about the scope and limits of information sharing is essential to maintain trust.

In addition, psychologists must be skilled in motivational and empathic communication techniques. This includes expressing concern without judgment, exploring ambivalence, and affirming client autonomy. These skills are essential

not only in direct care but also in educating partners and advocating for system-level change.

Documentation should also reflect ethical communication. Notes should be factual, respectful, and avoid stigmatizing language. When documenting risk, psychologists should distinguish between clinical impressions and client self-report and include rationale for decisions.

In supervisory and training settings, psychologists must model ethical communication for students and trainees. This includes discussions about countertransference, systemic bias, and ethical dilemmas encountered in the treatment of OUD.

Special Considerations in Informed Consent and Decision-Making

Informed consent is a cornerstone of ethical practice and requires particular attention when treating clients with OUD, especially those who may be mandated to treatment or experiencing cognitive impairments from substance use. The APA Ethics Code emphasizes that consent must be based on an understanding of the nature of the treatment, its risks and benefits, and the voluntary nature of participation.

Psychologists must ensure that consent is not only legally valid but also ethically sound. This involves checking for comprehension, revisiting consent periodically, and being sensitive to power dynamics. Clients under legal supervision or guardianship may face coercion, which complicates voluntary participation. In such cases, psychologists should document the steps taken to ensure informed, autonomous decision-making.

When working with adolescents or individuals with cognitive impairments, assent and surrogate consent may be necessary. However, the psychologist's role remains centered on safeguarding the client's rights and dignity.

Additionally, clients who are prescribed MOUD may face stigma or skepticism within treatment settings. Psychologists must clearly explain the evidence base for these medications and support client choices around pharmacotherapy. Treatment plans should reflect collaborative decision-making, not prescriptive authority.

Cultural Adaptation of Interventions

Psychosocial interventions for OUD must be adapted to be culturally relevant without compromising their core components. Cognitive-behavioral therapy (CBT), motivational interviewing (MI), and contingency management (CM) have strong evidence bases but were primarily developed within Western contexts.

Cultural adaptation involves modifying the delivery, content, and context of these interventions to align with the client's worldview. For instance, CBT may integrate spiritual values or family involvement in collectivist cultures. MI's emphasis on autonomy can be aligned with cultural values of dignity and self-determination.

Cultural adaptations of cognitive behavioral therapy for opioid use disorder often involve modifying examples, metaphors, and relational dynamics to reflect the client's cultural identity while maintaining core CBT principles such as cognitive restructuring and behavioral skill development. For example, when working with clients from collectivist cultural backgrounds, therapists may frame relapse prevention not only in terms of individual coping but also in relation to family roles, interdependence, and communal responsibility. Cognitive restructuring exercises might explore beliefs such as "I have brought shame to my family" and integrate culturally meaningful values like restoration of honor, relational repair,

and community contribution. Behavioral activation plans can incorporate culturally grounded activities, such as participation in faith-based gatherings, traditional healing practices, or community service, as protective factors supporting sobriety. In Indigenous or spiritually oriented communities, CBT interventions may incorporate storytelling traditions or culturally relevant proverbs to reframe maladaptive beliefs, thereby increasing engagement and resonance without altering the underlying cognitive model.

Using metaphors, stories, and analogies from the client's cultural background can enhance resonance and retention. Likewise, the role of family, elders, and community leaders may be central in decision-making and support. Psychologists should be open to co-constructing treatment plans with clients and incorporating cultural wisdom.

In research settings, cultural adaptation is increasingly being recognized as an ethical imperative. Inclusion of diverse populations in clinical trials, consultation with community stakeholders, and transparent reporting of cultural considerations are necessary to enhance the relevance and effectiveness of treatment for all populations.

Addressing Structural Barriers and Social Determinants of Health

Ethical and culturally competent care for OUD must acknowledge the broader social determinants that contribute to substance use and recovery outcomes. These include housing instability, poverty, discrimination, and lack of access to healthcare.

Psychologists are ethically obligated to address these factors in treatment planning and advocacy. This may involve connecting clients to resources, coordinating with case managers, or addressing trauma and stress related to systemic oppression.

In therapy, psychologists can explore the ways that environmental stressors exacerbate substance use and empower clients to build resilience. Psychoeducation, advocacy, and community engagement are ethical extensions of the psychologist's role.

Systems-level interventions may include advocating for harm reduction policies, supporting Medicaid expansion, or participating in interdisciplinary initiatives to improve access to culturally responsive care.

Conclusion

Working with clients with OUD requires psychologists to navigate a landscape shaped by ethical complexity, cultural diversity, and the need for effective communication. Grounded in APA's ethical principles, psychologists must ensure that their practice is competent, respectful, and responsive to each client's unique background and needs.

By fostering cultural competence, confronting stigma, and engaging in collaborative, ethical communication, psychologists can play a transformative role in addressing the opioid epidemic. Moreover, they can advocate for systems of care that are just, inclusive, and grounded in evidence-based practice.

This section has provided a comprehensive framework for understanding and applying these principles. In doing so, it prepares psychologists to engage in meaningful, ethical, and culturally attuned work with one of the most vulnerable populations in mental health today.

Section 7: Navigating National Guidelines and Policy Updates: Implications for Psychologists in Opioid Use Disorder Treatment

Introduction

Over the past decade, the landscape of opioid use disorder (OUD) treatment has shifted significantly due to growing recognition of the opioid epidemic as a national public health emergency. Federal agencies, including the Substance Abuse and Mental Health Services Administration (SAMHSA), the Centers for Disease Control and Prevention (CDC), and the Department of Health and Human Services (HHS), have responded by developing and regularly updating guidelines that promote evidence-based care, expand access to treatment, and reduce stigma. Psychologists, though not prescribers, have a vital role in interpreting, aligning with, and implementing these guidelines in clinical practice. This section provides a comprehensive overview of national policy shifts related to OUD, outlines updated treatment standards, and discusses how psychologists can engage with policy frameworks to enhance care, advocacy, and interdisciplinary collaboration.

National Strategic Frameworks: From Crisis Response to Public Health Integration

The U.S. government's approach to the opioid crisis has evolved from short-term emergency responses to long-term strategies emphasizing prevention, treatment, and recovery. One of the most significant frameworks has been the HHS 5-Point Strategy to Combat the Opioid Crisis, first released in 2017 and updated in subsequent years. This strategic plan centers around improving access to

treatment and recovery services, promoting overdose-reversing drugs, strengthening public health surveillance, supporting research on pain and addiction, and advancing better practices for pain management (HHS, 2021).

Complementing this initiative, the White House Office of National Drug Control Policy (ONDCP) has released annual National Drug Control Strategies, which increasingly call for the integration of behavioral health and substance use treatment. These policies stress a public health approach that reduces punitive practices and emphasizes equity, prevention, and recovery-oriented systems of care. Psychologists should be familiar with these high-level policy trends as they signal the direction of funding, program development, and expectations for integrated care delivery.

The CDC Clinical Practice Guidelines for Prescribing Opioids

In 2022, the CDC released an updated version of its landmark Clinical Practice Guidelines for Prescribing Opioids for Pain. While these guidelines primarily target medical providers, they significantly impact behavioral health by altering how patients access opioids, experience pain management, and potentially develop OUD.

The updated guidelines explicitly caution against abrupt opioid discontinuation and advocate for a patient-centered approach that balances benefits and risks of opioid therapy. Key changes include:

- Emphasis on shared decision-making.
- Flexibility for clinicians based on individual patient circumstances.
- Recommendations to avoid misapplication of dosage thresholds.

For psychologists, these guidelines underscore the importance of being aware of how pain management trends affect clients and collaborating closely with medical providers. Importantly, the CDC promotes non-pharmacologic interventions (e.g., cognitive behavioral therapy for pain) as first-line treatments, creating opportunities for psychologists to be core contributors to pain management and OUD prevention efforts.

SAMHSA's Medications for Opioid Use Disorder (MOUD) Guidelines

SAMHSA's Treatment Improvement Protocol (TIP) 63 on *Medications for Opioid Use Disorder* is one of the most comprehensive guidance documents currently available. Originally released in 2018 and updated multiple times, including a 2022 supplement, TIP 63 outlines best practices for the use of medications such as methadone, buprenorphine, and naltrexone in treating OUD.

Although psychologists do not prescribe MOUD, they play a critical role in behavioral interventions that accompany these treatments. TIP 63 emphasizes:

- The combination of MOUD and behavioral therapy as the gold standard.
- Trauma-informed and culturally responsive care models.
- Coordination between medical, behavioral, and social service providers.
- Reducing barriers to MOUD access, such as stigma and regulatory hurdles.

Furthermore, the 2023 updates reduced the requirements for prescribing buprenorphine, removing the X-waiver requirement. This policy shift expands access by allowing more healthcare providers to offer MOUD, which increases the likelihood that psychologists will encounter clients using these medications and should be prepared to coordinate care accordingly.

ASAM's National Practice Guideline for the Treatment of OUD

The American Society of Addiction Medicine (ASAM) has long been a leader in establishing clinical guidelines for the treatment of substance use disorders. The 2020 Focused Update of ASAM's National Practice Guideline for the Treatment of Opioid Use Disorder is a critical resource that provides evidence-based recommendations on diagnosis, pharmacological treatment, psychosocial interventions, and ongoing recovery support.

Of particular relevance to psychologists are the guideline's emphasis on:

- Comprehensive biopsychosocial assessments.
- Integration of trauma-informed and gender-responsive care.
- Use of contingency management and cognitive-behavioral strategies.
- Co-treatment of psychiatric disorders.

ASAM encourages interdisciplinary team-based approaches, positioning psychologists as essential partners in delivering whole-person care. By aligning their clinical practices with ASAM's guidelines, psychologists can help ensure continuity, fidelity, and quality of care for individuals with OUD.

APA's Role and Advocacy Efforts

The American Psychological Association (APA) has significantly expanded its role in the opioid crisis response over the past decade. APA's advocacy includes pushing for broader insurance coverage of behavioral health treatments, supporting interdisciplinary models, and developing training and resources for psychologists to work competently in the addiction field.

APA's 2020 policy brief *"How Psychologists Can Impact the Opioid Epidemic"* (Yaugher et al., 2020) laid out practical recommendations, including:

- Expanding access to evidence-based psychological treatments.
- Participating in training on substance use disorders.
- Engaging in community outreach and harm reduction education.
- Reducing stigma around substance use through public messaging.

Additionally, APA has partnered with federal agencies on workforce development programs, including continuing education sections and fellowships, to increase psychologists' preparedness in addressing substance use disorders. Their ongoing Government Relations Advocacy Updates (e.g., O'Connor, 2024) keep members informed of relevant legislation, funding streams, and policy changes that directly affect practice.

Interpreting Policy through a Health Equity Lens

A growing policy emphasis has been placed on addressing disparities in opioid-related outcomes. Data from the CDC (2023) and SAMHSA reveal that while white individuals were once most heavily affected by opioid overdose, mortality rates among Black, Hispanic, and Indigenous populations have risen sharply in recent years.

To respond, national policies now stress:

- Funding for community-based programs tailored to underserved populations.
- Expansion of harm reduction services in racially and ethnically diverse communities.

- Support for trauma-informed and culturally responsive care models.
- Inclusion of social determinants of health in treatment planning.

Psychologists must understand these policy shifts and adapt assessment and intervention strategies accordingly. This includes advocating for equitable resource allocation, avoiding cultural bias in diagnosis, and partnering with community organizations that address structural barriers to care.

Insurance Parity, Telehealth, and Regulatory Changes

Major policy updates have also impacted how services are delivered and reimbursed. Key regulatory shifts include:

- **The Mental Health Parity and Addiction Equity Act (MHPAEA):** Enforced more rigorously in recent years, this law mandates equal coverage for behavioral health and physical health services. Psychologists must ensure that clients are not denied appropriate treatment due to insurance discrimination.
- **Telehealth Expansion:** During the COVID-19 pandemic, federal and state governments enacted emergency rules expanding telehealth access for substance use treatment. Many of these rules have become permanent, enabling psychologists to deliver therapy remotely across state lines in some cases.
- **Licensure Portability:** The PSYPACT compact has grown to include over 30 states, improving psychologists' ability to serve clients in need of specialized care for OUD.

These changes offer psychologists both new responsibilities and new freedoms. Practitioners should stay updated on state licensure policies, billing codes for substance use services, and documentation standards aligned with federal policy.

Integrating Guidelines into Everyday Practice

While national policies and guidelines provide a framework, effective integration into clinical work requires ongoing education, systems-level thinking, and self-awareness. Psychologists can apply these standards in daily practice by:

- Using screening tools aligned with federal recommendations (e.g., NIDA Quick Screen, DAST-10).
- Coordinating with MOUD providers through integrated care models.
- Participating in case consultations and learning collaboratives related to OUD.
- Seeking continuing education that reflects APA, SAMHSA, and ASAM guidance.

Additionally, psychologists should document treatment plans and progress in a manner that reflects compliance with these standards. Ethical considerations, including informed consent, confidentiality in multidisciplinary settings, and client autonomy, must also be interpreted through the lens of evolving policies.

Future Directions in Policy and Psychology Practice

Emerging policies are increasingly focused on prevention, early intervention, and youth substance use. Recent guidance highlights the importance of universal screening in schools, trauma-informed youth mental health programming, and family-focused prevention initiatives (Fishbein & Sloboda, 2023). Psychologists

working in pediatric, school, or family therapy settings are encouraged to align their practices with these trends.

The integration of behavioral health into primary care, justice reform measures to improve care in correctional settings, and policies targeting housing and employment barriers for individuals with OUD will also reshape practice environments. As these changes unfold, psychologists must remain agile, informed, and active participants in policy advocacy.

Conclusion

National guidelines and policies have transformed the treatment landscape for opioid use disorder, offering both challenges and opportunities for psychologists. By grounding their practice in current evidence, aligning with interdisciplinary treatment models, and advocating for policy that centers equity and access, psychologists can play a pivotal role in addressing the opioid epidemic. Staying informed about regulatory changes, reimbursement policies, and evolving federal frameworks ensures that psychologists remain ethical, effective, and empowered contributors to public health.

Section 8: Applied Case Examples: Assessment, Intervention, and Interdisciplinary Collaboration in Opioid Use Disorder Treatment

Introduction

While theoretical models and clinical guidelines provide critical frameworks for addressing opioid use disorder (OUD), the complexity of real-world practice demands nuanced understanding and flexible application of these principles.

Psychologists frequently encounter individuals with OUD across a variety of settings, primary care, community mental health, correctional institutions, schools, and private practices, often presenting with co-occurring mental health issues, trauma histories, or social determinants that complicate recovery.

This section uses applied case vignettes to illustrate how psychologists can integrate evidence-based assessment methods, psychosocial interventions, and ethical decision-making into interdisciplinary care models. Each case highlights distinct populations, challenges, and treatment environments, drawing from contemporary research and national best practices. Through these examples, psychologists will deepen their understanding of how to tailor interventions to individual needs while engaging in collaborative treatment planning.

Case Example 1: Young Adult with Co-Occurring Anxiety and OUD in a University Counseling Center

Jasmine, a 23-year-old graduate student, presents to a university counseling center following a referral from the student health clinic after a non-fatal opioid overdose. Jasmine initially sought care for anxiety and panic attacks but disclosed during intake that she has been using non-prescribed oxycodone for the past year. The onset of opioid use was tied to a back injury she sustained during her final year of undergrad; she reports continuing use for “stress relief” and managing social anxiety. She meets DSM-5-TR criteria for moderate opioid use disorder and generalized anxiety disorder.

The psychologist in this setting conducts a comprehensive assessment using the Drug Abuse Screening Test (DAST-10) and the Beck Anxiety Inventory (BAI). A semi-structured interview reveals a pattern of opioid misuse during high-stress periods and social events. The psychologist consults with the primary care provider and campus psychiatrist to initiate a shared care plan.

Intervention focuses on integrated treatment using cognitive-behavioral therapy (CBT) for both anxiety and relapse prevention. Jasmine also participates in brief motivational interviewing (MI) sessions to address ambivalence about seeking medication-assisted treatment (MAT). Weekly interdisciplinary meetings at the counseling center enable coordinated care. Over six months, Jasmine transitions from illicit opioid use to receiving buprenorphine-naloxone (Suboxone) through a campus-affiliated prescriber while continuing CBT and psychoeducation.

This case underscores the importance of early screening, trauma-informed assessment, and coordinated behavioral-medical care. The psychologist's role in this case includes not only delivering evidence-based treatment but also acting as a liaison to ensure communication among providers, especially as Jasmine navigates multiple service systems.

Case Example 2: Middle-Aged Male in Rural Primary Care with Chronic Pain and OUD

Tom is a 47-year-old White male living in a rural community, referred to an integrated behavioral health provider within a primary care practice. Tom initially sought care for chronic lower back pain following a workplace injury but was flagged by his primary physician for opioid misuse after attempting to refill an old prescription early and expressing agitation during a pain consultation.

During the behavioral health intake, the psychologist uses the ASSIST (Alcohol, Smoking and Substance Involvement Screening Test) and PHQ-9. Tom expresses shame and frustration, believing he is being judged for "needing pain meds to function." He meets the criteria for mild OUD and has a score on the PHQ-9 consistent with moderate depression. The psychologist introduces psychoeducation about the interplay between pain, mood, and substance use, emphasizing a biopsychosocial model.

Treatment begins with Acceptance and Commitment Therapy (ACT) focused on chronic pain and values-driven action, along with behavioral activation strategies. Tom is hesitant about MOUD but eventually agrees to begin extended-release naltrexone after support from the interdisciplinary care team, which includes his physician, a nurse care manager, and the on-site psychologist. Case conferencing among team members ensures consistency in messaging and treatment goals.

Over time, Tom develops a healthier narrative about managing pain and begins vocational rehabilitation. His opioid use declines, depressive symptoms lessen, and he becomes more engaged in community life. This case illustrates how psychologists working in rural, resource-limited settings can play a vital role in reshaping treatment narratives, engaging in motivational strategies, and supporting interdisciplinary collaboration.

Case Example 3: Adolescent with Polysubstance Use and Family Conflict in Outpatient Mental Health

Luis is a 16-year-old Latinx male referred to a community outpatient clinic by his high school counselor after a school suspension for possessing oxycodone and vaping THC. His mother reports behavioral changes over the past six months, including irritability, social withdrawal, and decline in academic performance. During intake, Luis admits to using “whatever pills he can get,” mostly with peers, and sometimes to help with sleep or stress. He denies physical dependence but shows signs of tolerance and psychological distress.

The psychologist conducting the intake uses the CRAFFT screening tool, validated for adolescent substance use, and collaborates with a bilingual family therapist. Assessment also includes exploration of Luis’s academic, cultural, and family dynamics. His father was recently deported, and the family faces housing

insecurity. The psychologist uses a trauma-informed lens to frame substance use as a coping strategy rather than a moral failing.

Given his developmental stage and family context, Luis is enrolled in Multidimensional Family Therapy (MDFT), which includes family psychoeducation, communication training, and behavioral contracts. Individual sessions use motivational enhancement therapy (MET) and trauma-sensitive CBT. The psychologist works closely with school personnel, probation officers, and a pediatrician, advocating for community resources such as youth mentorship programs and food assistance.

This case demonstrates the value of developmentally appropriate assessment, culturally responsive intervention, and systems-level coordination. Luis's improvements stem not only from individual therapy but from family stabilization and the building of a restorative support network.

Case Example 4: Perinatal Woman in Recovery Facing Relapse Risk and Custody Concerns

Chanel is a 29-year-old Black woman in her third trimester of pregnancy, referred by her obstetrician for behavioral health support after expressing fears of relapse and potential Child Protective Services (CPS) involvement. She has a prior history of heroin use and has been on methadone maintenance therapy for the past eight months. Chanel reports past trauma, including domestic violence, and previously lost custody of a child during an earlier period of untreated addiction.

The integrated care team includes an OB-GYN, a social worker, a nurse midwife, and a clinical psychologist with specialization in perinatal mental health and trauma. The psychologist uses the Edinburgh Postnatal Depression Scale (EPDS) and Life Events Checklist (LEC) as part of a broader trauma-informed perinatal

assessment. Chanel shows signs of elevated stress, insomnia, and complex grief related to past experiences.

Therapeutic goals include relapse prevention, trauma processing, and parenting readiness. The psychologist uses Seeking Safety, a manualized treatment for PTSD and substance use, tailored to perinatal clients. Concurrently, she engages Chanel in mindfulness-based cognitive therapy (MBCT) and prepares a postpartum wellness plan in collaboration with the nursing team.

This interdisciplinary approach ensures Chanel's care is non-punitive, empowering, and aligned with harm reduction principles. Communication between providers focuses on recovery support rather than surveillance, which fosters trust. Chanel delivers a healthy baby, remains engaged in treatment postpartum, and begins reunification planning for her older child.

This case highlights the ethical imperative to protect both maternal and infant well-being, the centrality of trauma-informed care, and the need for psychologists to counter systemic biases that often criminalize substance use during pregnancy.

Case Example 5: Incarcerated Individual with OUD and Reentry Planning Needs

Derrick, a 34-year-old Black man, is incarcerated in a medium-security facility and referred for mental health services after two infractions related to aggression and withdrawal symptoms. He reports a long history of heroin use and has cycled through the criminal justice system multiple times. His last overdose was two weeks before his current incarceration. He also discloses symptoms consistent with PTSD due to witnessing a violent death as a child.

Incarceration settings often lack comprehensive OUD services. In Derrick's facility, there is no access to methadone or buprenorphine. However, a contract

psychologist advocates for expanding access to evidence-based interventions. The psychologist conducts a structured clinical interview and screens for trauma and suicidality using the PTSD Checklist for DSM-5 (PCL-5) and Columbia-Suicide Severity Rating Scale (C-SSRS).

With permission, the psychologist coordinates care with a correctional case manager and a reentry navigator. Derrick begins individual therapy focused on CBT for substance use and emotion regulation, and enrolls in a group using motivational interviewing to prepare for reentry. The team develops a discharge plan that includes linkage to a local federally qualified health center (FQHC) that offers MOUD, housing referral, and legal aid.

This case reflects systemic barriers to care in correctional institutions, but also the potential for advocacy and interdisciplinary collaboration to facilitate meaningful reentry planning. Psychologists must navigate ethical tensions between care and custody, advocate for best practices in resource-limited settings, and work to disrupt cycles of recidivism fueled by untreated addiction.

Clinical Reflections and Implications for Psychologists

These five case examples represent a diverse spectrum of clients with opioid use disorder, emphasizing developmental, cultural, systemic, and clinical complexity. Despite varied backgrounds and presenting issues, several unifying themes emerge:

1. The Central Role of Assessment

Each case highlights the importance of comprehensive, culturally informed, and trauma-sensitive assessment. Psychologists must go beyond symptom checklists to understand the social and structural contexts in which opioid use emerges.

Tools such as the DAST, ASSIST, CRAFFT, and C-SSRS should be used in conjunction with interviews and collateral data to form a robust clinical picture.

2. Integrated and Interdisciplinary Care

Psychologists are most effective when they function as part of interdisciplinary teams. Collaboration with prescribers, social workers, case managers, and peers improves treatment continuity and helps address multifaceted needs such as housing, employment, legal support, and parenting. Psychologists often serve as care coordinators, communication bridges, and advocates within these systems.

3. Evidence-Based Intervention Flexibility

No single treatment approach fits all clients with OUD. The cases demonstrate how CBT, MI, ACT, trauma-informed care, MBCT, Seeking Safety, and MDFT can be tailored to match client goals, cognitive readiness, and cultural frameworks. Equally, non-traditional interventions, like integrating spirituality or peer mentorship, may hold cultural resonance and therapeutic value.

4. Ethical Considerations

Across all cases, psychologists must navigate confidentiality, dual relationships, informed consent, and non-maleficence, particularly in high-risk or mandated settings. Supporting autonomy while managing safety requires clinical maturity, ethical awareness, and ongoing consultation or supervision.

5. Addressing Health Disparities and Structural Barriers

Clients from marginalized backgrounds often face heightened risks and reduced access to care. Psychologists must be proactive in addressing systemic barriers, whether it is advocating for harm reduction resources in prisons, challenging child welfare stigmas against pregnant women, or building culturally competent care teams.

Conclusion

Psychologists treating clients with opioid use disorder must integrate diagnostic precision, cultural humility, clinical flexibility, and system-level collaboration. The real-world case examples presented here offer practical guidance for applying these principles in diverse settings, from college campuses and outpatient clinics to prisons and perinatal health systems.

Importantly, psychologists must remain engaged in continuing education, policy advocacy, and reflective practice to meet the evolving needs of individuals impacted by the opioid crisis. The work is complex, but through sustained commitment to ethical, evidence-based, and culturally responsive care, psychologists can significantly contribute to recovery, resilience, and justice for individuals and communities affected by opioid use disorder.

Section 9: Course Summary, Integration, and Future Directions in Opioid Use Disorder Treatment for Psychologists

Introduction

Over the past several sections, this course has examined the multifaceted nature of the opioid epidemic and the evolving role of psychologists in the treatment of opioid use disorder (OUD). This final section brings together the major clinical, ethical, and systemic themes explored throughout the training. Drawing from the latest research and national practice guidelines, this section aims to synthesize content for reflective practice and prepare psychologists for continued engagement in effective, ethical, and equitable care for individuals affected by opioid use.

Opioid use disorder is not a singular clinical challenge but a dynamic intersection of neurobiology, trauma, structural inequity, public policy, and individual suffering. As such, the role of the psychologist is equally complex, requiring a combination of clinical expertise, cultural humility, ethical reasoning, and collaborative leadership.

This section provides a comprehensive summary of the course's primary learning objectives and closes with a discussion of future directions in research, training, clinical innovation, and health systems change.

Integration of Core Themes

The Complexity and Scope of the Opioid Crisis

At the outset of this course, we established the scope and scale of the opioid epidemic, emphasizing both its medical and social dimensions. Over 100,000 overdose deaths occur annually in the United States, with synthetic opioids such as fentanyl playing an increasingly dominant role (CDC, 2023). However, these deaths are not merely the result of pharmacological exposure, they reflect a larger pattern of social dislocation, chronic pain, trauma, despair, and systemic failure.

Psychologists must understand the biopsychosocial nature of OUD. Opioids affect the brain’s reward system in ways that hijack motivation and decision-making, especially in the presence of early adversity and mental health conditions. However, treatment must go beyond symptom management. The relational and systemic contexts of opioid misuse, poverty, racism, stigma, incarceration, and under-resourced communities, must be central to any effective intervention.

The public health framing of OUD requires psychologists to expand their conceptualization of the problem beyond pathology. This includes understanding social determinants of health and addressing policy-level contributors such as

access to care, criminalization of substance use, and disparities in medical treatment.

Assessment and Diagnosis: Clinical Tools in Cultural Context

Section 2 emphasized comprehensive and culturally attuned assessment as the foundation of ethical and effective care. Tools such as the ASSIST, DAST-10, PHQ-9, PCL-5, and CRAFFT provide useful screening frameworks, but they are most effective when interpreted within the client's cultural, developmental, and systemic context.

Psychologists must consider how social marginalization, systemic trauma, and provider bias can lead to both over-pathologizing and under-identification of OUD. Assessment is not a neutral process, it reflects the worldview of the clinician, the trust level of the client, and the structures in which care is embedded. As such, the therapeutic relationship becomes part of the assessment itself, with particular importance placed on safety, transparency, and mutual respect.

Clients from minoritized communities may underreport use due to stigma or mistrust, particularly in carceral, child welfare, or medically coercive environments. Clinicians must build rapport over time and use narrative and ecological approaches to understand the client's relationship to opioids, mental health systems, and help-seeking behavior.

The Co-Occurrence of Mental Health Conditions

As highlighted in Section 3, comorbidity between OUD and psychiatric disorders is the rule, not the exception. Depression, anxiety, PTSD, and personality disorders are common among individuals with OUD and significantly influence treatment outcomes. These conditions often predate substance use and can be both a precipitant and a consequence of opioid misuse.

Psychologists must be able to disentangle overlapping symptom presentations, particularly when withdrawal effects mimic or mask psychiatric symptoms. Importantly, untreated mental illness, especially when combined with chronic pain or trauma, greatly increases the risk of overdose, relapse, and suicide.

Integrated treatment approaches, such as combined CBT and medication-assisted treatment (MAT), trauma-informed care models, and mindfulness-based therapies, show the strongest outcomes for clients with co-occurring disorders. Psychologists must be prepared to address both disorders concurrently and to work closely with medical providers to ensure consistency in messaging, safety planning, and care delivery.

Evidence-Based Interventions and Collaborative Models

Section 4 detailed the range of psychosocial interventions with empirical support for OUD, including cognitive behavioral therapy (CBT), motivational interviewing (MI), contingency management (CM), mindfulness-based interventions (MBIs), and acceptance and commitment therapy (ACT). These therapies offer critical tools for addressing the behavioral, emotional, and motivational dimensions of recovery.

No single intervention fits all clients, and psychologists must be flexible in tailoring approaches to individual needs, cultural frameworks, and stages of change. The therapeutic relationship remains the foundation of effective care, particularly in the context of stigma, trauma, and mistrust.

Collaboration is equally important. Psychologists working in integrated care settings (e.g., primary care, FQHCs, hospitals, criminal justice) are increasingly part of interdisciplinary teams involving prescribers, case managers, peer specialists, and social workers. Interdisciplinary collaboration enhances continuity, reduces

redundancy, and increases treatment engagement, particularly when coordinated through shared plans and regular communication.

Sections 4 and 7 also emphasized the growing use of telehealth, mobile health (mHealth), and digital therapeutics, which can increase access for rural and underserved populations. Psychologists must be trained in digital competencies and aware of privacy, accessibility, and efficacy considerations in technology-mediated care.

Harm Reduction and Ethical Considerations

One of the most profound shifts in substance use care is the mainstreaming of harm reduction approaches. As discussed in Section 5, harm reduction is not antithetical to recovery, it is an evidence-based, humanistic, and pragmatic approach that saves lives and increases engagement in care.

Psychologists may struggle with tension between abstinence-based frameworks and harm reduction principles. However, APA's ethical guidelines (APA, 2017) support client autonomy, dignity, and beneficence. As such, clinicians should meet clients where they are and respect incremental goals, whether that means reducing use, switching from injection to oral use, or carrying naloxone.

Ethical challenges also arise in mandated settings, perinatal care, and when working with clients at high risk for overdose or suicide. Psychologists must navigate limits of confidentiality, dual roles, and systemic constraints while advocating for the least restrictive and most client-centered path forward. Trauma-informed ethics requires attention not only to the individual but to the systems shaping their options, outcomes, and risks.

Cultural Competence and Health Equity

Section 6 underscored the critical role of cultural competence in effective OUD treatment. Psychologists must recognize the cultural meanings of substance use, the impact of intergenerational trauma, and the structural inequities that differentially affect communities of color, Indigenous populations, LGBTQ+ individuals, and immigrants.

Cultural humility, an ongoing commitment to learning, reflection, and partnership, is more than an ethical add-on; it is central to therapeutic effectiveness. Interventions must be adapted, not merely translated, to reflect the client's worldview, community norms, and relational dynamics. Collaborative models such as community-based participatory research, peer-led services, and tribal behavioral health programs offer valuable frameworks for equitable care.

Language matters. Using person-first, recovery-oriented language reduces stigma and communicates respect. Documentation should reflect this ethos, particularly in settings (e.g., criminal justice or child welfare) where records may have legal implications.

Future Directions for Psychologists in OUD Treatment

As the landscape of OUD care evolves, psychologists are uniquely positioned to lead and innovate in several critical areas:

Expanded Roles in Integrated and Medical Settings

With the shift toward behavioral health integration in medical care, psychologists will increasingly work in hospitals, primary care, and emergency departments. Training programs must prepare psychologists to assess OUD, deliver brief interventions, and collaborate with medical teams. Licensure and billing policies

must evolve to support psychologists in these roles, including for telehealth and digital service delivery.

Advocacy and Systems Change

Psychologists have a voice in shaping policy. Through research, professional organizations, and clinical leadership, psychologists can advocate for evidence-based drug policy, expanded access to MOUD, elimination of racial disparities in treatment, and investment in harm reduction infrastructure.

This includes challenging policies that criminalize addiction, supporting decriminalization efforts, and calling for systemic reforms in policing, incarceration, and child welfare that disproportionately harm people who use drugs.

Training and Workforce Development

Psychology graduate and internship programs must include substantive training in substance use assessment, harm reduction, cultural humility, and interdisciplinary collaboration. Continuing education, mentorship, and reflective supervision are critical to ensure ethical and effective practice in a rapidly changing field.

The psychologist workforce must also diversify to reflect the populations most affected by OUD. Recruitment and retention efforts focused on BIPOC clinicians, LGBTQ+ providers, and providers with lived experience will enhance cultural resonance and reduce barriers to care.

Research and Evaluation

Psychologists are trained researchers and are well-positioned to evaluate interventions, analyze systemic outcomes, and contribute to implementation science. Future research must prioritize real-world effectiveness, culturally

tailored interventions, and mixed-methods studies that capture both outcomes and lived experience.

Areas of needed research include:

- Trauma-informed models for OUD
- Intersections of chronic pain and addiction
- Protective factors in recovery maintenance
- Peer-led and community-based programs
- Youth and family-focused prevention models

Conclusion

The opioid epidemic presents a profound and enduring challenge to mental health professionals, health systems, and communities. Psychologists, with their expertise in behavior, trauma, systems, and ethics, are essential to the national response. This course has offered a comprehensive and integrated foundation for engaging in that work.

From assessment and diagnosis to trauma-informed intervention and policy advocacy, psychologists are called to lead with compassion, integrity, and a commitment to equity. The work is difficult and ongoing, but it is also deeply meaningful. By centering human dignity, clinical science, and collaborative practice, psychologists can help forge a future in which recovery is possible, harm is reduced, and every person is treated with respect and care.

References

Alpert, A. B., CichoskiKelly, E. M., & Fox, A. D. (2017). What lesbian, gay, bisexual, transgender, queer, and intersex patients say doctors should know and do: a qualitative study. *Journal of homosexuality*, *64*(10), 1368-1389.

American Psychological Association. (2017). *Ethical Principles of Psychologists and Code of Conduct*. https://www.apa.org/ethics/code

American Society of Addiction Medicine (ASAM). (2020). *National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update*. https://www.asam.org/Quality-Science/clinical-guidelines

Back, S. E., Gros, D. F., McCauley, J. L., Cox, E., & Baldwin, S. A. (2018). Integrated cognitive behavioral therapy for co-occurring posttraumatic stress disorder and substance use disorder among veterans: A randomized controlled trial. *Journal of Dual Diagnosis*, *14*(3), 129–141.

Bergman, B. G., Fallah-Sohy, N., & Hoffman, L. A. (2019). Psychosocial approaches in the treatment of opioid use disorders. In *Opioid Addiction* (pp. 105–125). Springer.

Bohnert, A. S., Ilgen, M. A., Louzon, S., et al. (2019). Substance use disorders and suicide risk in the U.S. Veterans Health Administration. *Addiction*, *114*(7), 1193–1202.

Bohnert, K. M., Ilgen, M. A., Louzon, S., McCarthy, J. F., & Katz, I. R. (2019). Substance use disorders and the risk of suicide mortality among men and women in the US Veterans Health Administration. *Addiction*, *114*(7), 1193–1202.

Boness, C. L., Gonzalez, J. C., Sleep, C., & Singh, R. S. (2024). Evidence-based assessment of substance use disorder. *Psychological Assessment*, *36*(1), 34–49. https://doi.org/10.1177/10731911231177252

Centers for Disease Control and Prevention. (2023). *Provisional Drug Overdose Death Counts*. National Center for Health Statistics. https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm

Dellazizzo, L., Potvin, S., Giguère, S., & Landry, C. (2023). Meta-review on the efficacy of psychological therapies for the treatment of substance use disorders. *Psychiatry Research*, *319*, 114915.

Department of Health and Human Services (HHS). (2021). *HHS 5-Point Strategy to Combat the Opioid Crisis*. https://www.hhs.gov/opioids/about-the-epidemic/hhs-response/index.html

Durpoix, A., Rolling, J., Coutelle, R., & Lalanne, L. (2024). Psychotherapies in opioid use disorder: Toward a step-care model. *Journal of Neural Transmission*, *131*(1), 45–61.

Ezell, J. M., Simek, E., Shetty, N., & Pho, M. T. (2024). A scoping review of the utilization of opioid use treatment, harm reduction, and culturally tailored interventions among racial/ethnic minorities in the United States. *Journal of Substance Use & Health and Addiction*. https://doi.org/10.1007/s11469-024-01373-2

Felitti, V. J., Anda, R. F., Nordenberg, D., Williamson, D. F., Spitz, A. M., Edwards, V., … & Marks, J. S. (1998). Relationship of childhood abuse and household dysfunction to many of the leading causes of death in adults. *American Journal of Preventive Medicine*, *14*(4), 245–258.

Fish, J. N. (2020). Future directions in understanding and addressing mental health among LGBTQ youth. *Journal of Clinical Child & Adolescent Psychology*, *49*(6), 943-956.

Fishbein, D. H., & Sloboda, Z. (2023). A national strategy for preventing substance and opioid use disorders through evidence-based prevention programming. *Clinical Child and Family Psychology Review*, *26*(2), 135–154. https://doi.org/10.1007/s10567-022-00420-5

Gainsbury, S. M. (2017). Cultural competence in the treatment of addictions: Theory, practice and evidence. *Clinical Psychology & Psychotherapy*, *24*(4), 987–1001. https://doi.org/10.1002/cpp.2062

Green, A. E., DeChants, J. P., Price, M. N., & Davis, C. K. (2022). Association of gender-affirming hormone therapy with depression, thoughts of suicide, and attempted suicide among transgender and nonbinary youth. *Journal of adolescent health*, *70*(4), 643-649.

Guerrero, E. G., Khachikian, T., & Frimpong, J. A. (2019). Drivers of continued implementation of cultural competence in substance use disorder treatment. *Journal of Substance Abuse Treatment*, *103*, 64–72. https://doi.org/10.1016/j.jsat.2019.05.004

Haibach, J. P., Beehler, G. P., Dollar, K. M., & Finnell, D. S. (2014). Moving toward integrated behavioral intervention for treating multimorbidity among chronic pain, depression, and substance-use disorders. *Medical Care*, *52*(Suppl 5), S50–S58.

Ilgen, M. A., Bohnert, A. S. B., Ignacio, R. V., McCarthy, J. F., Valenstein, M., Kim, H. M., & Blow, F. C. (2016). Psychiatric diagnoses and risk of suicide in veterans. *Archives of General Psychiatry*, *67*(11), 1152–1158.

Krawczyk, N., Rivera, B. D., Jent, V., Keyes, K. M., Jones, C. M., & Cerdá, M. (2022). Has the treatment gap for opioid use disorder narrowed in the US?: A yearly assessment from 2010 to 2019". *International Journal of Drug Policy*, *110*, 103786.

López, L. M., & Melian, J. (2024). Culturally competent assessment and treatment of substance use disorders in Latinx American communities. *Professional Psychology: Research and Practice*. https://psycnet.apa.org/record/2025-16183-009

Murphy, J. G., Peter, S. C., Witkiewitz, K., Hand, S. B., & Thomas, F. (2023). Testing contingency management and an integrated behavioral economic and mindfulness intervention. *Trials*, *24*(1), 176.

Najavits, L. M. (2015). *Seeking Safety: A Treatment Manual for PTSD and Substance Abuse*. Guilford Press.

O'Connor, K. (2024). APA's Government, Policy, and Advocacy Update. *Psychiatric News*, *59*(3). https://psychiatryonline.org/doi/full/10.1176/appi.pn.2024.03.3.13

Peter, S. C., Murphy, J. G., Witkiewitz, K., Hand, S. B., & Thomas, F. (2023). Integrated behavioral economic and mindfulness intervention for buprenorphine adherence. *Trials*, *24*(1), 185.

Redmond, M. L., Lewis, R. K., Parker, T., & Canare, R. (2024). Culturally competent substance use treatment for Black American communities. *Psychology of Addictive Behaviors*, *38*(2), 89–102. https://doi.org/10.1037/adb0000830

Sayegh, P., Vivian, D., Heller, M. B., & Kirk, S. (2023). Racial, cultural, and social injustice in psychological assessment: A brief review, call to action, and resources to help reduce inequities and harm. *Professional Psychology:*

Research and Practice. https://psycnet.apa.org/fulltext/2023-74567-001.html

Scialanca, M., Alexander, K., & Tofighi, B. (2025). Digital psychosocial interventions tailored for people in OUD treatment. *Journal of Medical Internet Research*, *27*(1), e69538.

Substance Abuse and Mental Health Services Administration (SAMHSA). (2022). *TIP 42: Treatment of Co-Occurring Substance Use Disorders and Mental Health Disorders*. U.S. Department of Health and Human Services.

Substance Abuse and Mental Health Services Administration (SAMHSA). (2022). *Medications for Opioid Use Disorder (TIP 63)*. https://store.samhsa.gov/product/TIP-63

Volkow, N. D., Koob, G. F., & McLellan, A. T. (2016). Neurobiologic advances from the brain disease model of addiction. *New England Journal of Medicine*, *374*(4), 363–371.

Welsh, J. W., Mataczynski, M. J., & Nguyen, M. D. (2020). A review of behavioral therapies in adolescents with opioid use disorder. *Harvard Review of Psychiatry*, *28*(5), 346–358.

West, A. E., Telles, V., Antony, V., & Zeledon, I. (2022). An opioid and substance use disorder needs assessment study for American Indian and Alaska Native youth in California. *Psychology of Addictive Behaviors*, *36*(4), 301–317 https://doi.org/10.1037/adb0000806

Witkiewitz, K., McCallion, E., Vowles, K. E., & Murphy, J. G. (2023). Cognitive behavioral therapy for opioid use disorder: A review of evidence and future directions. *Addiction*, *118*(2), 213–223.

Wong-Padoongpatt, G., King, A., & Zane, N. (2024). Culturally competent assessment and treatment of substance use disorders for Asian American communities. *Professional Psychology: Research and Practice*. https://psycnet.apa.org/record/2025-16183-007

Yaugher, A. C., Bench, S. W., & Meyers, K. J. (2020). How psychologists can impact the opioid epidemic. *Professional Psychology: Research and Practice*, *51*(5), 495–506. https://doi.org/10.1037/pro0000309

Zerden, L. S., Guan, T., & Lombardi, B. M. (2020). Psychosocial interventions in office-based opioid treatment: A systematic review. *Journal of the Society for Social Work and Research*, *11*(3), 456–475.